| Section | Name | Details |
| A5.02.08 | Consider first line dressings appropriate to wound bed type and exudate level | |
| A5.05.02 | Consider standard interactive dressings first | |
| A5.06.01 | Consider standard interactive dressings first. Dressings advised by TVN | |
| A5.10 | Consider standard dressings first | |
| 02.02.01 | Bendroflumethiazide | 2.5mg dose (higher doses are not indicated in hypertension) |
| 02.05.01 | Minoxidil tablets Loniten® | |
| 13.14.06 | Salicylic acid 5% w/w in emulsifying ointment | |
| 10.02.01 | 3,4,diaminopyridine | Hospital only |
| A5.15 | 3M Cavilon Durable Barrier Cream | Skin protectant Type of wound product is suitable for Intact skin As a barrier against bodily fluids, prevention of skin damage associated with incontinence Can be used alongside containment products Can be used to prevent friction to vulnerable areas of skin Frequency of use Reapply sparingly twice daily Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Do not use on infected skin Not be used as an emollient Not to be used around the peri wound Can increase adherence of some dressing products and therefore care should be taken when adhesive products are being used in conjunction with the cream on people with fragile skin Rationale for inclusion in formulary The only barrier cream that can be used in conjunction with containment products without blocking the absorption of the pad Cost effective, does not require reapplication at every episode of hygiene |
| A5.15 | 3M Cavilon No Sting Barrier Film Pump Spray and applicators | Protective transparent barrier film Type of wound product is suitable for Superficial broken skin and abrasions As a barrier against bodily fluids, prevention of skin damage associated with incontinence Can be used alongside containment products Can be used to prevent friction to vulnerable areas of skin Can be used on superficial abrasions caused by incontinence Can be used to protect peri wound from exudate Can be used to protect against aggressive adhesive products Can be used to protect the skin surrounding stoma sites Frequency of use Every 72 hours Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Do not use on infected skin Allow product to dry before applying the containment products, dressings or clothing (30 seconds) Too many layers can make the area of skin feel stiff Can affect electrode readings in the treated area Rationale for inclusion in formulary Available in a foam applicator and spray to aid application Non sticky after use Can be used on broken areas of skin Cost effective, does not require reapplication at every episode of hygiene |
| 05.03.01 | Abacavir Ziagen® | |
| 05.03.01 | Abacavir and Lamivudine Kivexa® | |
| 10.01.03 | Abatacept Orencia® | Hospital only Available via Home Care |
| 08.01.05 | Abemaciclib Verzenios® | In line with NICE |
| 08.03.04.02 | Abiraterone Zytiga® | |
| 04.10.01 | Acamprosate Campral EC® | |
| 02.08.02 | Acenocoumarol Sinthrome® | |
| 02.02.07 | Acetazolamide | Itracranial hypertension |
| 11.06 | Acetazolamide | |
| 11.06 | Acetazolamide | Hospital Only |
| 11.06 | Acetazolamide M/R | |
| 12.01.01 | Acetic Acid 2% Earcalm ® |
|
| 20 | Acetic Acid Solution 3% |
|
| 03.07 | Acetylcysteine | Hospital Only |
| 11.08.01 | Acetylcysteine 10% eye drops | |
| 11.08.01 | Acetylcysteine 5% with Hypromellose 0.35% Ilube® | |
| 05.03.02.01 | Aciclovir oral | |
| 05.03.02.01 | Aciclovir injection | |
| 11.03.03 | Aciclovir 3% eye ointment | |
| 13.10.03 | Aciclovir 5% cream | |
| 13.05.02 | Acitretin | |
| 03.01.02 | Aclidinium Eklira Genuair® | |
| 03.01.04 | Aclidinium / formoterol inhaler Duaklir Genuair® | |
| A5.08.07 | Actico® | Cohesive inelastic high compression bandage. Short stretch bandage Type of wound product is suitable for Venous leg ulceration Lymphoedema Management of chronic oedema Duration dressing remains on wound before changing Daily to 7 days Frequency of dressing change Dependant on exudate levels if wound present or oedema management. Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Not recommended on those patients with an ABPI lower than 0.8. Caution in diabetic patients Caution when cardiac overload or renal failure present or suspected. Rationale for inclusion in formulary Only cohesive short stretch bandage. Nurses competent in its usage. |
| A5.02.01 | ActiForm Cool | Hydrogel Sheet Type of wound product is suitable for Necrotic or sloughy wounds that require hydration and cooling pain relief Can be used on dry wounds with the backing left in place Cut to shape of the wound Requires a secondary dressing Duration dressing remains on wound before changing 1-3 days if dressings become discoloured or opaque or at first signs of exudate strike through Frequency of dressing change If dressing becomes discoloured or opaque or at first signs of exudate strike through. Do not allow to dry out Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Should not be used as a covering for deep narrow cavities or sinuses. Do not use on infected wounds. Not suitable for heavily exuding wounds Known product or component sensitivity Not for application on ischaemic wounds Rationale for inclusion in formulary Dry necrotic, sloughy or painful wounds For ease of application - sheet gel rather than liquid Primary dressing Can be used prior to larval therapy to maintain moisture levels |
| A5.03.01 | Actilite (Honey Dressing) | Non-adherent viscose net dressing 99% Manuka honey and 1% Manuka oil. Type of wound product is suitable for A primary dressing for low to moderate shallow exuding wound with light slough. Granulating or epithelialising wounds with clinical signs of infection. Requires a secondary dressing. Max Duration dressing remains on wound before changing 3-7 Days Frequency of dressing change 3 to 7 days depending on exudate Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Known allergy to Bee Venom and Honey products Blood sugars should be monitored in patients with diabetes Stinging sensation may be experienced. If unacceptable for patient then discontinue. Rationale for inclusion in formulary For antimicrobial and de-sloughing properties Ease of application Can be cut to size Easy removal in one piece Availability of different sizes Not found to be harmful to peri-wound skin Malodour Cost effective |
| A5.02.05 | ActivHeal Foam | Two layer dressing consisting of a polyurethane bacterial barrier membrane with a centrally located hydrophilic pad +/- acrylic adhesive border. Type of wound product is suitable for Moderately exuding wounds with signs of granulation, epithelialisation or slough. Can be used as primary or secondary Duration dressing remains on wound before changing 1-7 days Frequency of dressing change Up to 7 days dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Full thickness burns Surgical implantations Rationale for inclusion in formulary Cost effective Simple to use on the foot and digits Can be cut to shape |
| A5.02.05 | ActivHeal Foam (Tracheostomy) | Tracheostomy foam dressing Type of wound product is suitable for ActivHeal Foam Tracheostomy dressing has a fenestration, which allows the dressing to fit neatly around a tracheostomy tube. The dressing can also be used around intubation and cannula insertion procedures, external bone fixators and appropriately-sized wound drainage tubes. Duration dressing remains on wound before changing Dependant on clinical need and soiling Frequency of dressing change Up to 7 days, dependant on clinical need and soiling Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Do not use if reaction to any of its components Rationale for inclusion in formulary Specific dressing shaped and able to cut for tracheostomies. Cost effective |
| A5.03.01 | Activon ®Tube | 100% medical grade Manuka Honey. Type of wound product is suitable for Use as topical treatment for infected sloughy shallow or cavity wounds. Primary or addition to other Activon products. Requires secondary dressing. Max Duration dressing remains on wound before changing Up to 4 days Frequency of dressing change Daily in acute infection Up to 4 days in chronic infection dependant on exudate Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Wounds with active blood loss Known allergies to bee Venom and Honey products Blood sugars should be monitored in diabetic patients Stinging sensation may be experienced – discontinue if not tolerant. Rationale for inclusion in formulary Anti-microbial and de-sloughing properties Control of odours Benefit of adding to other action products and increasing honey Suitable for use in cavities Cost effective |
| A5.03.01 | Activon Tulle (Honey Dressing) | Knitted viscose mesh impregnated with 100% Manuka Honey. Type of wound product is suitable for Creates a moist healing environment effectively eliminates odour. Provides anti-microbial action. Debrides and de-sloughs shallow wounds where the exudate level has started to decrease. Requires secondary dressing Max Duration dressing remains on wound before changing Up to 4 days Frequency of dressing change Daily in acute infection Up to 4 days for chronic infection depending on exudate Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Wounds with active blood loss Known allergies to bee Venom and Honey products Blood sugars should be monitored in diabetic patients Stinging sensation may be experienced – discontinue if not tolerant. Rationale for inclusion in formulary Anti-microbial and de-sloughing properties for wounds with reduced levels of exudate. Control of odours Ease of application and removal in one piece Can be cut to size Available to various size Cost effective |
| 01.05.03 | Adalimumab Humira® | Injection For specialist use only in line with NICE guidance below |
| 10.01.03 | Adalimumab Humira® | Hospital only |
| 11.99.99.99 | Adalimumab Humira® | In line with NICE |
| 13.05.03 | Adalimumab | |
| 13.06.01 | Adapalene | |
| 13.06.01 | Adapalene with benzoyl peroxide Epiduo® | |
| 05.03.03 | Adefovir Dipivoxil Hepsera® | |
| 02.03.02 | Adenosine injection | |
| 03.04.03 | Adrenaline / epinephrine EpiPen® | There are currently supply issues with adrenaline autoinjectors (October 2018) - See SPS for updates |
| 03.04.03 | Adrenaline / Epinephrine Jext® | |
| 03.04.03 | Adrenaline/Epinephrine (Emerade ®) | |
| 08.01.05 | Afatinib Giotrif® | |
| 11.08.02 | Aflibercept Eylea® | |
| 04.03.04 | Agomelatine Valdoxan® | |
| 05.05.08 | Albendazole | |
| 08.01.05 | Alectinib | In line with NICE |
| 08.02.03 | Alemtuzumab Lemtrada® | In line with NICE |
| 06.06.02 | Alendronic Acid Binosto® |
|
| 06.06.02 | Alendronic Acid tablets |
|
| 09.06.04 | Alfacalcidol injection | |
| 09.06.04 | Alfacalcidol oral preparations | |
| 07.04.01 | Alfuzosin Hydrochloride | |
| A5.03.01 | Algivon (Honey Dressing) | Alginate dressing impregnated with 100% Manuka Honey. Type of wound product is suitable for Primary dressing for infected, shallow cavity wounds, particularly if necrotic or malodorous with moderate exudate. Requires secondary dressing. Max Duration dressing remains on wound before changing Up to 4 days for chronic infection Frequency of dressing change Daily for acute infection Up to 4 days for chronic infection/depending upon exudate Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Wounds with active blood loss Known allergy to be venom and honey products Blood sugars should be monitored in diabetic patients Stinging sensation may be experienced – discontinue if not tolerated Rationale for inclusion in formulary Antimicrobial and de sloughing properties Absorbent Malodour Ease of application and removal in one piece Can be cut to size Available in various sizes Can be shaped to wound size and depth Cost effective |
| 03.04.01 | Alimemazine | Second line- in children as per guidance |
| 02.12 | Alirocumab Praluent® | To be used in line with NICE TA393 |
| 02.05.05.03 | Aliskiren Rasilez® | Supported by RICaD, see link below. |
| 13.05.01 | Alitretinoin Toctino® | |
| A5.03.03 | Allevyn Ag® | A non adherent foam dressing impregnated with silver sulphadiazine that can be cut to suit the patient Type of wound product is suitable for For use around infected pin sites Duration dressing remains on wound before changing Daily or as directed Frequency of dressing change Daily Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Patients who have a known sensitivity to Silver Sulphadiazine or Sulphonamides Females who are at or near full term pregnancy or lactating Not for use on neonates or new born infants during the first month of life Rationale for inclusion in formulary Used around infected pin sites in patients with external metalwork to help reduce bacterial load HOSPITAL USE ONLY |
| A5.02.05 | Allevyn Cavity | Type of wound product is suitable for Wound management by secondary intention on acute, chronic, full thickness or partial thickness or shallow granulating wounds including pressure ulcers, leg ulcers, diabetic foot ulcers, malignant wounds surgical wounds, malignant wounds donor sites and fungating ulcers Can be used as a primary or secondary dressing Duration dressing remains on wound before changing Can stay in place up to 3-7 days Frequency of dressing change Dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) In common with all adhesive products, some cases of irritation and/or maceration of the skin may occur. It should be noted that inappropriate use or too frequent dressing changes, particularly in patients with fragile skin, can result in skin stripping. If this occurs change to the Allevyn gentle border range. If redness or sensitisation occur, discontinue use Caution under compression when exudate levels are moderate to high. Rationale for inclusion in formulary Can be used for low to moderate exudate levels Different sizes and shapes available Cost effective |
| A5.02.03 | Allevyn Life | Hydrocellular foam dressing Type of wound product is suitable for Shallow granulating wounds, acute and chronic exuding wounds, full and partial thickness wounds such as leg ulcer, malignant wound, surgical wound. Primary dressing Silicone adhesive Duration dressing remains on wound before changing Up to 7 days dependent on dressing indicators Frequency of dressing change Up to 3 times a week maximum Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Do not use with oxidising agents such as hypochlorite solutions or hydrogen peroxide Discontinue if reddening or sensitivity occurs. Do not cut Caution under compression where exudate levels are moderate to high Rationale for inclusion in formulary Fragile skin with absorbency and conformability, problematic healing wounds. Odour control. |
| A5.02.05 | Allevyn Non-Adhesive | Type of wound product is suitable for Wound management by secondary intention on acute, chronic, full thickness or partial thickness or shallow granulating wounds including pressure ulcers, leg ulcers, diabetic foot ulcers, malignant wounds surgical wounds, malignant wounds donor sites and fungating ulcers Can be used as a primary or secondary dressing Duration dressing remains on wound before changing Can stay in place up to 3-7 days Frequency of dressing change Dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) In common with all adhesive products, some cases of irritation and/or maceration of the skin may occur. It should be noted that inappropriate use or too frequent dressing changes, particularly in patients with fragile skin, can result in skin stripping. If this occurs change to the Allevyn gentle border range. If redness or sensitisation occur, discontinue use Caution under compression when exudate levels are moderate to high. Rationale for inclusion in formulary Can be used for low to moderate exudate levels Different sizes and shapes available Cost effective |
| A5.02.05 | Allevyn range | Available in adhesive, non adhesive and gentle Type of wound product is suitable for Wound management by secondary intention on acute, chronic, full thickness or partial thickness or shallow granulating wounds including pressure ulcers, leg ulcers, diabetic foot ulcers, malignant wounds surgical wounds, malignant wounds donor sites and fungating ulcers Can be used as a primary or secondary dressing Duration dressing remains on wound before changing Can stay in place up to 3-7 days Frequency of dressing change Dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) In common with all adhesive products, some cases of irritation and/or maceration of the skin may occur. It should be noted that inappropriate use or too frequent dressing changes, particularly in patients with fragile skin, can result in skin stripping. If this occurs change to the Allevyn gentle border range. If redness or sensitisation occur, discontinue use Caution under compression when exudate levels are moderate to high. Rationale for inclusion in formulary Can be used for low to moderate exudate levels Different sizes and shapes available Cost effective |
| 09.05.01.01 | Alliance Calcium Syrup® | |
| 10.01.04 | Allopurinol | |
| 06.01.02.03 | Alogliptin Vipidia▼® | |
| 07.01.01.01 | Alprostadil Prostin VR® | |
| 07.04.05 | Alprostadil cream Vitaros® | Specialist initiation |
| 07.04.05 | Alprostadil Intracavernosal injection | |
| 02.10.02 | Alteplase | |
| 09.04 | Altraplen Compact® (formally known as Nutriplen®) |
|
| 13.12 | Aluminimum Salts | |
| 09.05.02.02 | Aluminium Hydroxide | |
| 04.09.01 | Amantadine Hydrochloride | |
| 05.01.04 | Amikacin | |
| 02.02.03 | Amiloride Hydrochloride | |
| 03.01.03 | Aminophylline Phyllocontin Continus® | |
| 03.01.03 | Aminophylline IV | |
| 02.03.02 | Amiodarone injection | |
| 02.03.02 | Amiodarone tablets | |
| 04.02.01 | Amisulpride (oral) | |
| 04.03.01 | Amitriptyline | |
| 04.07.03 | Amitriptyline | |
| 04.07.04.02 | Amitriptyline | |
| 02.06.02 | Amlodipine | |
| 13.10.02 | Amorolfine 5% nail lacquer | ££ |
| 03.13 | Amoxicillin | Hospital only |
| 05.01.01.03 | Amoxicillin injection | |
| 05.01.01.03 | Amoxicillin oral presentations | |
| 03.13 | Amphotericin Fungizone® | Hospital only |
| 05.02 | Amphotericin lipid complex infusion | |
| 05.02 | Amphotericin infusion | |
| 11.03.02 | Amphotericin (eye) | |
| 09.01.04 | Anagrelide Xagrid® | |
| 10.01.03 | Anakinra Kineret® | Hospital only |
| 04.07.04.01 | Analgesics Migraleve Pink ® | |
| 08.03.04.01 | Anastrozole | |
| 06.04.01.01 | Angeliq® |
|
| 05.02.04 | Anidulafungin | |
| 01.01.01 | Antacid and Oxetacaine | Suspension Specialist use only |
| 13.08.01 | Anthelios XL® Melt- in cream SPF 50+ | Non-formulary if not for ACBS approved indication |
| 14.05 | Anti-D (Rh0) Immunoglobulin | |
| 14.05.03 | Anti-D (Rh0) Immunoglobulin | |
| 01.07.02 | Anusol-HC | |
| 02.08.02 | Apixaban | APC preferred agent: this recommendation must only be taken into account after a patient and prescriber have discussed all treatment options (including warfarin) and only if they have no preference about which medicine they want to use. Following diagnosis of AF- use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD. RICaD: Apixaban in AF Use following Hip and Knee surgery- full course of treatment supplied on discharge. For the treatment and secondary prevention of DVT and/or PE - use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD. RICaD: Apixaban in DVT/ PE |
| 04.09.01 | Apomorphine | |
| A5.16 | Appeel ® | available in 4 different applications Type of wound product is suitable for Adhesive dressing or appliance removal where skin stripping, loss of skin integrity and pain is a concern Frequency of use Use at each dressing change Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Should not be used when there is a known sensitivity to any of the ingredients If in doubt, patch test a small area, prior to use The product is flammable and should be used in a well ventilated area Avoid use around, flames and sources of ignition Rationale for inclusion in formulary For pain free removal of dressings where fragile skin is a concern |
| 11.08.02 | Apraclonidine 1% SDU eye drops | |
| 11.08.02 | Apraclonidine 0.5% | |
| 13.05.03 | Apremilast | |
| 04.06 | Aprepitant Emend® | |
| 09.04 | Aptamil Pepti® 1 |
|
| 09.04 | Aptamil Pepti® 2 |
|
| 09.04 | Aptamil Pepti® Junior | |
| A5.02.04 | Aquacel range | Type of wound product is suitable for Moderate to heavy exudate, sloughy, necrotic or granulating wounds. Available in rope for cavities Duration dressing remains on wound before changing Maximum 7 days Frequency of dressing change 1-7 days depends on clinical need Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Not suitable for dry wounds. Non dissolvable. Known product or component sensitivity Do not cut Rationale for inclusion in formulary Aids debridement of slough or necrotic tissue Remains intact so easily removed in one piece Absorbs exudate which aids most wound healing facilitating atraumatic dressing change, Cost effective |
| A5.03.03 | Aquacel® Ag + Extra range | Hydrofibre with silver Type of wound product is suitable for Management of clinically infected, sloughy, necrotic or granulating wounds with moderate to heavy exudate. Moderate to highly exuding wounds. Aquacel Ag Plus Extra can be used to break down biofilms Requires a secondary dressing Duration dressing remains on wound before changing Dependent upon exudate 1 - 7 days Frequency of dressing change Dependent upon level of exudate and clinical presentation Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Should not be used on individuals who are sensitive to or have had an allergic reaction to the dressing or its components. Not suitable for dry wounds. No haemostatic properties. Rationale for inclusion in formulary Specialist antimicrobial product Moderate to high exudate levels Can be used to break down biofilms Remains intact on wound bed and easily removable in one piece (non dispersible) |
| 13.02.01 | Aquadrate® | Contains 10% urea Over the counter preparation suitable for self-care/purchase if appropriate |
| A5.02.01 | AquaForm | Hydrogel: Clear viscose sterile gel Aids autolytic debridement and removal of devitalised tissue. Type of wound product is suitable for Low exuding, necrotic or sloughy wounds Duration dressing remains on wound before changing Up to 3 days Frequency of dressing change 1-3 days Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Not suitable for heavily exuding wounds. Caution known product or component sensitivity. Full thickness burns or infected wounds Not for application to ischaemic wounds Rationale for inclusion in formulary Required for wound beds that need donation of moisture to rehydrate the wound bed and debride. Cost effective |
| 07.03.04 | Arcing spring diaphragm | |
| 04.02.02 | Aripiprazole Abilify Maintena® | The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer. |
| 04.02.01 | Aripiprazole tablets | |
| 08.01.05 | Arsenic Trioxide Trisenox® |
|
| 05.04.01 | Artemether with lumefantrine Riamet® | |
| 15.02 | Articaine Hydrochloride with Adrenaline Septanest® | |
| 09.06.03 | Ascorbic Acid | |
| 09.08.01 | Asfotase alfa | In line with NICE Highly Specialised Technology guidance |
| 02.09 | Aspirin (antiplatelet) Dispersible | |
| 04.07.01 | Aspirin 300mg dispersible tablets | |
| 05.03.01 | Atazanavir Reyataz® | |
| 02.04 | Atenolol | |
| 08.02.03 | Atezolizumab Tecentriq® | |
| 04.04 | Atomoxetine Strattera® | Please note that commissioning discussion is underway. However the present status is as follows:- Birmingham CrossCity CCG, Birmingham South Central CCG, Sandwell & West Birmingham CCG Supported with an ESCA- Solihull CCG |
| 02.12 | Atorvastatin tablets | |
| 07.01.03 | Atosiban Tractocile® | |
| 05.04.08 | Atovaquone | |
| 09.04 | Atraplen® Protein (formally known as Nutriplen® Protein) |
|
| A5.01.01 | Atrauman | Type of wound product is suitable for For flat granulating and epithelising wound for non to heavy exudate where adherence may occur. To be used as a primary dressing with a secondary for absorption. Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change 1-7 days, depending on levels of exudate Caution/contraindications (when not to use the dressing, patient groups to avoid etc. Known product or component sensitivity Rationale for inclusion in formulary Used to reduce adherence to wound bed. Most cost effective non adherent dressing. Dressing impregnated with neutraltriglycerides to prevent penetration of granulation tissue. Petroleum free. |
| A5.03.03 | Atrauman Ag® | Non adherent Primary Dressing containing metallic silver Type of wound product is suitable for For clinically infected shallow, granulating wounds with low exudate. To be used as a primary dressing with a secondary for absorption. Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change 1-7 days, depending on levels of exudate Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Known product or component sensitivity Must be removed prior to x-ray, ultrasound, diathermy and MRI Rationale for inclusion in formulary Used to reduce adherence to wound bed with clinical signs of infection Most cost effective non adherent dressing containing silver. Dressing impregnated with neutral triglycerides to prevent penetration of granulation tissue. Petroleum free. Specialist Recommendation |
| 01.02 | Atropine | Injection |
| 15.01.03 | Atropine SF solution | |
| 15.01.03 | Atropine sulphate | |
| 11.05 | Atropine Sulphate 0.5% drops | |
| 11.05 | Atropine Sulphate 1% drops | |
| 11.05 | Atropine Sulphate single use Minims® | |
| 15.01.03 | Atropine tablets | |
| 13.02.01 | Aveeno cream® |  £££- Paediatrics only £££- Recommended by specialist for oncology use only. |
| 10.01.03 | Avelumab Bavencio ® | In line with NICE Hospital only |
| 07.04.05 | Aviptadil 25mcg / Phentolamine 2mg Invicorp® | |
| 08.02.04 | Axicabtagene ciloleucel YESCARTA® |
|
| 09.04 | Aymes® Complete |
|
| 09.04 | Aymes® Creme |
|
| 09.04 | Aymes® Shake/Savoury |
|
| 08.01.03 | Azacitidine Vidaza® | |
| 01.05.03 | Azathioprine | Tablets 25mg, 50mg Maintenance of remission of acute ulcerative colitis and Crohn’s disease in adults– unlicensed but in line with national guidelines. For use in Inflammatory Bowel Disease (IBD) as per effective shared care agreement (ESCA). See link below. |
| 03.12 | Azathioprine | |
| 04.13 | Azathioprine | Specialist use only for neurological conditions |
| 08.02.01 | Azathioprine | |
| 10.01.03 | Azathioprine | Supported by ESCA, see link below. |
| 13.05.03 | Azathioprine (dermatology) |
|
| 13.06.01 | Azelaic Acid 15% gel Finacea® | |
| 13.06.01 | Azelaic Acid 20% cream Skinoren® | |
| 11.04.02 | Azelastine Optilast® | |
| 12.02.01 | Azelastine and fluticasone Dymista | Follow treatment algorithm |
| 05.01.05 | Azithromycin |
|
| 05.01.05 | Azithromycin |
|
| 11.03.01 | Azithromycin Azyter® | |
| 05.01.02.03 | Aztreonam | |
| 10.02.02 | Baclofen | |
| 10.02.02 | Baclofen intrathecal | Hospital only |
| 13.02.01.01 | Balneum Plus ®Bath Additive | Over the counter preparation suitable for self-care/purchase if appropriate |
| 13.02.01 | Balneum® Plus cream |
Over the counter preparation suitable for self-care/purchase if appropriate |
| 01.05.01 | Balsalazide Sodium Colazide® | ££££££ |
| 03.01.01.01 | Bambuterol tablets Bambec® | Specialist initiation for severe brittle asthma/ cystic fibrosis |
| 10.01.03 | Baricitinib ® Olumiant | In line with NICE |
| 09.04 | Basecal® |
|
| 14.04 | BCG vaccine diagnostic agent | |
| 14.04 | BCG vaccine Intradermal | |
| 03.02 | Beclometasone and formoterol Fostair®NEXThaler® | |
| 03.02 | Beclometasone and formoterol Fostair® | |
| 03.02 | Beclometasone Dipropionate Clenil Modulite® | |
| 12.02.01 | Beclometasone Dipropionate nasal preparations | |
| 03.02.03 | Beclometasone/formoterol/glycopyrronium Trimbow® | COPD Appendix 4 - Criteria for triple therapy and for triple inhaler use in COPD
|
| 03.04.02 | Bee and Wasp Allergen Extracts Pharmalgen® | |
| 08.01.01 | Bendamustine | |
| A5.02.04 | BeneHold TASA | Approved April 2019 Hydrocolloid Range with film border |
| 03.14 | Benralizumab | In line with NICE |
| 13.06.01 | Benzoyl Peroxide | |
| 13.06.01 | Benzoyl Peroxide 3% with Clindamycin 1% Duac® Once Daily | |
| 13.06.01 | Benzoyl Peroxide 5% with Clindamycin 1% Duac® Once Daily | |
| 12.03.01 | Benzydamine 0.15% oral rinse | |
| 12.03.01 | Benzydamine 0.15% oral spray | |
| 05.01.01.01 | Benzylpenicillin | |
| 05.01.01.01 | Benzylpenicillin Benzathine | |
| 04.06 | Betahistine Dihydrochloride | |
| 06.03.02 | Betamethasone | |
| 13.04 | Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 3% Diprosalic Ointment® | Potency: potent |
| 13.04 | Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 3% Diprosalic Scalp Application® | Potency: potent |
| 13.04 | Betamethasone (as Valerate) 0.025% Betnovate-RD Ointment® | Potency: Moderate |
| 13.04 | Betamethasone (as Valerate) 0.025% Betnovate-RD Cream® | Potency: Moderate |
| 13.04 | Betamethasone (as Valerate) 0.1% Betnovate ® | Potency: Potent |
| 13.04 | Betamethasone (as Valerate) 0.1% with Fucidic Acid 2% Fucibet cream® | Potency: potent |
| 11.04.01 | Betamethasone 0.1% eye drops | |
| 11.04.01 | Betamethasone 0.1% eye ointment | |
| 12.01.01 | Betamethasone 0.1% with Neomycin 0.5% ear drops | |
| 11.04.01 | Betamethasone 0.1% with Neomycin 0.5% eye drops | |
| 13.04 | Betamethasone Dipropionate 0.064% with Clotrimazole 1% Lotriderm® | Potency: potent |
| 12.01.01 | Betamethasone ear drops | |
| 12.02.01 | Betamethasone Sodium Phosphate nasal preparations | |
| 09.04 | Betaquick® |
|
| 11.06 | Betaxolol 0.25% eye drops | |
| 11.06 | Betaxolol 0.5% Unit Dose Eye Drops | |
| 11.06 | Betaxolol 0.5% eye drops | |
| 07.04.01 | Bethanechol Chloride Myotonine® | |
| 08.01.05 | Bevacizumab | |
| 11.08.02 | Bevacizumab intravitreal injection Avastin® | |
| 08.01.05 | Bexarotene | |
| 02.12 | Bezafibrate | |
| A5.02.05 | Biatain dressings | Polyurethane foam dressing with bevelled edges Type of wound product is suitable for Moderately exuding wounds with signs of granulation, epithelialisation or slough. Can be used as primary or secondary Duration dressing remains on wound before changing 1-7 days Frequency of dressing change Up to 7 days dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Do not use with oxidising solutions such as hydrogen peroxide Full thickness burns Surgical implantations Rationale for inclusion in formulary Simple to use on the foot and digits Can be cut to shape |
| 08.03.04.02 | Bicalutamide | |
| 11.06 | Bimatoprost 0.01% eye drops | |
| 11.06 | Bimatoprost with Timolol Ganfort® | |
| 12.03.05 | Biotene Oralbalance® Saliva replacement gel | Approved for |
| 06.01.01.02 | Biphasic Insulin Aspart NovoMix® 30 | |
| 06.01.01.02 | Biphasic Insulin Lispro Humalog® Mix | |
| 06.01.01.02 | Biphasic Isophane Insulin Humulin® M3 | |
| 06.01.01.02 | Biphasic Isophane Insulin Insuman® Comb | |
| 01.06.02 | Bisacodyl | Tablet E/C 5mg, Suppository 10mg |
| 12.04 | Bismuth Iodine Paraffin Paste BIPP ® | |
| 12.04 | Bismuth Subnitrate and Iodoform Paste for Gauze | |
| 01.03.03 | Bismuth subsalicylate Pepto Bismol® | For use in H Pylori eradication in penicillin allergy and previous clarithromycin, as per antimicrobial guidelines. |
| 02.04 | Bisoprolol | |
| 02.08.01 | Bivalirudin Angiox® | |
| 13.07 | Bleomycin | |
| 08.02.03 | Blinatumomab Blincyto® | In line with NICE |
| 06.01.06 | Blood Glucose Meters | |
| 05.03.03 | Boceprevir Victrelis® | |
| 12.03.01 | Bonjela Junior Dental Gel Bonjela® Junior | |
| 08.01.05 | Bortezomib Velcade® | |
| 02.05.01 | Bosentan Tracleer® | NHS England commissioned |
| 08.01.05 | Bosutinib Bosulif® | |
| 01.02 | Botulinium Toxin A | Achalasia
|
| 04.07.04.02 | Botulinum Toxin Type A botox® | |
| 13.12 | Botulinum toxin type A | |
| 14.04 | Botulism antitoxin | |
| 09.04.01 | Bread | Essential protein-free basic products. Necessary for children and adults with inborn errors of protein metabolism who tolerate very little natural protein. 1 slice ordinary bread = 4g protein and is not allowed in low protein diets. |
| 08.01.05 | Brentuximab vedotin Adcetris® |
|
| 08.01.05 | Brigatinib Alunbrig® | In line with NICE |
| 11.06 | Brimonidine Tartrate | |
| 11.06 | Brimonidine Tartrate 0.2% with Timolol 0.5% Combigan® | |
| 13.06.03 | Brimonidine tartrate gel Mirvaso® | |
| 11.06 | Brinzolamide 10mg/ml | |
| 11.06 | Brinzolamide 10mg/ml with Brimonidine 2mg/ml Simbrinza® | |
| 11.06 | Brinzolamide 10mg/ml with Timolol 5mg/ml | |
| 04.08.01 | Brivaracetam Briviact ® | |
| 04.08.01 | Brivaracetam Briviact® |
|
| 10.01.03 | Brodalumab Kyntheum ® | In line with NICE
|
| 11.08.02 | Bromfenac Yellox® | Approved January 2018. Interim measure due to supply issues with ketorolac eye drops |
| 06.07.01 | Bromocriptine | |
| 01.05.02 | Budesonide Budenofalk® | 2mg/dose foam enema Approved July 2018 |
| 03.02 | Budesonide | |
| 03.02 | Budesonide and formoterol Symbicort Turbohaler® | Non-Formulary for COPD |
| 01.05.02 | Budesonide capsules | |
| 01.05.02 | Budesonide MMX Cortiment® | |
| 02.02.02 | Bumetanide | |
| 04.07.02 | Buprenorphine patches |
|
| 04.10.03 | Buprenorphine S/L tablets > | |
| 04.07.02 | Buprenorphine sublingual tablets | For use in opioid dependence, see section 4.10.3 |
| 04.03.04 | Bupropion | |
| 04.10.02 | Bupropion Hydrochloride Zyban® | |
| 06.07.02 | Buserelin | |
| 08.03.04.02 | Buserelin | |
| 06.07.02 | Buserelin nasal spray | |
| 04.01.02 | Buspirone Hydrochloride | ££ Second line |
| 08.01.01 | Busulfan Tablets | |
| A5.02.02 | C View | Vapour-permeable adhesive film Type of wound product is suitable for Dry non infected wounds, retention of lines, fixation of secondary dressings, protection of intact skin, protection of skin against friction, protection of newly epithelialized wounds Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change Up to 7 days Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Clinically infected wounds, bleeding or exuding wounds Rationale for inclusion in formulary Retention of lines, protection of intact skin, fixation of other dressings. Waterproof |
| 03.04.03 | C1 esterase inhibitor Cinryze® | Hospital only- NHSE Commissioned |
| 03.04.03 | C1 esterase Inhibitor Berinert® | Hospital only- NHSE commissioned |
| 08.01.05 | Cabazitaxel Jevtana® | |
| 06.07.01 | Cabergoline | |
| 08.01.05 | Cabozantinib Cabometyx® | In line with NICE |
| 13.14.03 | Cade oil 12% w/w and salicylic acid 6% w/w in emulsifying ointment | |
| 03.05.01 | Caffeine citrate |  unlicensed |
| 09.04.01 | Cake, biscuits, and snacks | Important protein-free foods to provide important energy, assist dietary adherence and provide variety when natural protein tolerance is very limited. Necessary for children and adults with inborn errors of protein metabolism who tolerate very little natural protein. |
| 13.03 | Calamine Aqueous Cream | Over the counter preparation suitable for self-care/purchase if appropriate |
| 13.03 | Calamine Lotion | Over the counter preparation suitable for self-care/purchase if appropriate |
| 09.05.01.01 | Calcichew® | |
| 13.05.02 | Calcipotriol 50mcg/g ointment | |
| 13.05.02 | Calcipotriol 50mcg/ml scalp application | |
| 13.05.02 | Calcipotriol 50micrograms/g with Betamethasone 0.05% Dovobet Gel® | |
| 13.05.02 | Calcipotriol 50micrograms/g with Betamethasone 0.05% Dovobet ointment ® | Maximum 15g per day or 100g per week. Step down to calcipotrol oint as per NICE CG153 |
| 13.05.02 | Calcipotriol 50micrograms/g with Betamethasone 0.05mg/g Enstilar® | |
| 06.06.01 | Calcitonin (salmon) / Salcatonin | |
| 09.06.04 | Calcitriol | |
| 13.05.02 | Calcitriol 3micrograms/g Silkis® | |
| 09.06.04 | Calcium and Vit D preparations | |
| 09.05.02.02 | Calcium Salts | |
| 09.04 | Calogen® |
|
| 09.04 | Calogen® Extra |
|
| 09.04 | Calogen® Extra Shots |
|
| 06.01.02.03 | Canagliflozin Invokana▼® | SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis MHRA Alert: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes) |
| 02.05.05.02 | Candesartan cilexetil tablets | |
| 13.09 | Capasal® | Over the counter preparation suitable for self-care/purchase if appropriate |
| 08.01.03 | Capecitabine Tablets | |
| 12.03.01 | Caphosol® | |
| 05.01.09 | Capreomycin | |
| 04.07.03 | Capsaicin | For other strength, see section 10.3.2 |
| 10.03.02 | Capsaicin cream | Tier 2 , £££ |
| 10.03.02 | Capsaicin cream | see chapter 4.7.3 for neuropathic pain |
| 02.05.05.01 | Captopril tablets | For existing patients only |
| 04.02.03 | Carbamazepine | |
| 04.07.03 | Carbamazepine | |
| 04.08.01 | Carbamazepine | MHRA Advice Patients being treated for epilepsy should be maintained on a specific manufacturer's product- APC preferred brand is TEGRETOL |
| 06.02.02 | Carbimazole | |
| 03.07 | Carbocisteine | |
| A5.02.08 | CarboFLEX | Odour absorbent wound contact dressings containing activated charcoal Type of wound product is suitable for For the management of moderate to heavily exuding malodorous wounds including fungating Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change As exudate level determines Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Known sensitivity to the dressing or its components As soon as CarboFLEX becomes contaminated with exudate, odour control diminishes The underlying cause of wound odour should be identified prior to commencement of product Rationale for inclusion in formulary CarboFLEX is a layered dressing to provide higher levels of fluid handling On shallow or cavity wounds with moderate to heavy levels of exudate |
| 11.08.01 | Carbomers Clinitas Gel® | |
| 07.01.01 | Carboprost | |
| 09.04 | Carbzero |
|
| 08.01.05 | Carfilzomib Kyprolis® | In line with NICE |
| 11.08.01 | Carmellose 0.5% SDU Xailin Fresh ® | |
| 11.08.01 | Carmellose1% multi Moorfields | |
| 08.01.01 | Carmustine Gliadel® | |
| 02.04 | Carvedilol | |
| 05.02.04 | Caspofungin | |
| 05.01.02.01 | Cefalexin oral presentations |
|
| 05.01.02.01 | Cefotaxime injection |
|
| 03.13 | Ceftazidime | Hospital only |
| 05.01.02.01 | Ceftazidime | |
| 05.01.02.01 | Ceftriaxone | |
| 03.13 | Cefuroxime | Hospital only |
| 05.01.02.01 | Cefuroxime | |
| 11.03.01 | Cefuroxime | |
| 10.01.01 | Celecoxib | |
| A5.08.07 | Cellona® | Sub compression wadding bandage to pad and shape a limb prior to compression therapy Type of wound product is suitable for Provides padding for larger limbs under compression. Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change Daily up to weekly dependant on exudate and oedema management. Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Advised not to apply directly to skin as can cause irritation. Rationale for inclusion in formulary Cost effective for use in larger quantities when used in lymphoedema management. |
| 09.04.01 | Cereals | Essential protein-free basic products. Necessary for children and adults with inborn errors of protein metabolism who tolerate very little natural protein. 2 regular Weetabix = 4.5g protein and this protein amount is more than the amount of protein that may be tolerated. |
| 08.01.05 | Ceritinib Zykadia® | In line with NICE |
| 10.01.03 | Certolizumab Pegol Cimzia® | In line with NICE Hospital only Available via Home Care |
| 12.01.03 | Cerumol® | |
| 03.04.01 | Cetirizine | OTC preparation suitable for self-care/purchase if appropriate |
| 13.02.01 | Cetraben emollient cream® | Over the counter preparation suitable for self-care/purchase if appropriate |
| A5.13 | Cetraben Pump cream | Emollient containing white soft paraffin and light liquid paraffin Type of wound product is suitable for For inflamed, dry, chapped skin Frequency of use Daily Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Allergy or hypersensitivity to any of the ingredients Rationale for inclusion in formulary Treatment of dry skin Dermatology approved |
| 06.07.02 | Cetrorelix Cetrotide® | |
| 08.01.05 | Cetuximab Erbitux® | |
| 04.01.01 | Chloral Hydrate | |
| 08.01.01 | Chlorambucil Tablets | |
| 05.01.07 | Chloramphenicol injection | |
| 11.03.01 | Chloramphenicol | |
| 12.01.01 | Chloramphenicol ear drops | |
| 04.01.02 | Chlordiazepoxide | Adjunct in acute alcohol withdrawal |
| 04.10.01 | Chlordiazepoxide | |
| 13.11.02 | Chlorhexidine acetate 0.015% with cetrimide 0.15% Travasept 100® | |
| 12.03.04 | Chlorhexidine gluconate 0.2% mouthwash | |
| 12.03.04 | Chlorhexidine gluconate 1% dental gel | |
| 13.11.02 | Chlorhexidine gluconate preparations | |
| 12.02.03 | Chlorhexidine Hydrochloride 0.1%, Neomycin Suphate 0.5% Naseptin® | |
| 03.04.01 | Chlorphenamine |
OTC preparation suitable for self-care/purchase if appropriate |
| 04.02.01 | Chlorpromazine (oral) | |
| 04.06 | Chlorpromazine Hydrochloride | |
| 04.02.01 | Chlorpromazine injection | |
| 02.02.01 | Chlortalidone Tablets | |
| 14.04 | Cholera vaccine Dukoral® | |
| 12.03.01 | Choline Salicylate dental gel | |
| 06.05.01 | Choriogonadotropin Alfa Ovitrelle® | |
| A5.04.02 | Cica-Care | Silicone sheet for scar treatment Type of wound product is suitable for Not for use on open wounds- to be applied on healed scar only. This is not a dressing but a scar treatment Duration dressing remains on wound before changing 23 hours Frequency of dressing change Daily Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Do not use on open or infected wounds. Do not use on skin affected by acne. Discontinue use if a rash or itching occur. Rationale for inclusion in formulary Scar therapy Silicone sheets have been shown to soften, flatten scarring aiding movement, nerve sensations and function. Self adherent, Re-usable |
| 03.02 | Ciclesonide Alvesco® |
|
| 01.05.03 | Ciclosporin | Capsules 10mg, 25mg, 50mg, 100mg, IV infusion 50mg/ml Treatment of ulcerative colitis- for specialist use only MHRA specify that ciclosporin must be prescribed and dispensed by brand as bioavailability differences exist between brands |
| 04.13 | Ciclosporin | Specialist use only for neurological conditions |
| 08.02.02 | Ciclosporin Neoral® | Post transplant- new patients Post transplant-patients initiated pre April 2013 |
| 10.01.03 | Ciclosporin | Supported by ESCA, see link below. |
| 13.05.03 | Ciclosporin |
|
| 11.99.99.99 | Ciclosporin 2mg/g eye ointment Optimmune® | |
| 11.99.99.99 | Ciclosporin 1 mg/mL eye drops, emulsion Ikervis® | |
| 09.05.01.02 | Cinacalcet Mimpara® | |
| 04.06 | Cinnarizine tablets | |
| 05.01.12 | Ciprofloxacin infusion | |
| 05.01.12 | Ciprofloxacin oral presentations |
|
| 11.03.01 | Ciprofloxacin 0.3% | |
| 12.01.01 | Ciprofloxacin 0.3% drops | |
| 12.01.01 | Ciprofloxacin 2mg/ml ear drops Cetraxal® | |
| 04.03.03 | Citalopram oral drops |
|
| 04.03.03 | Citalopram tablets |
|
| 08.02.04 | Cladribine Mavenclad® | |
| 05.01.05 | Clarithromycin injection | |
| 05.01.05 | Clarithromycin oral presentations | |
| 06.04.01.01 | Climanor® | |
| 05.01.06 | Clindamycin Capsules |
|
| 07.02.02 | Clindamycin Dalacin® | |
| 13.06.02 | Clindamycin | |
| 13.06.01 | Clindamycin 1% gel Zindaclin® | Approved on formulary April 2018 To be reviewed in 12 months to assess clindamycin 1% solution supply issues. |
| 13.06.01 | Clindamycin 1% topical solution Dalacin T ® | |
| 05.01.06 | Clindamycin 300mg/2mL Injection | |
| A5.08.03 | Clinifast | ££ Elasticated Sub bandage lining Type of wound product is suitable for To be used under retention and compression bandages when conformity is required Can be used for wet/dry wrapping. Duration dressing remains on wound before changing As required Frequency of dressing change As required Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Ensure the correct size for a limb is selected Rationale for inclusion in formulary Cost effective choice when conformity to a limb is required |
| A5.07.03 | Clinipore | Permeable non woven, synthetic adhesive tape For securing bandages Frequency of dressing change Determined by wound type and dressing change Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) None listed Rationale for inclusion in formulary Available on drug tariff, cost effective and evaluated as meeting the requirements of a tape including adherence. |
| A5.02.08 | Clinisorb | Odour absorbent charcoal dressing Type of wound product is suitable for Malodourous wounds such as fungating wounds Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change 1-7 days dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Not indicated as a primary dressing in dry wounds Store at room temperature Exudate levels will reduce the effectiveness of the charcoal Rationale for inclusion in formulary Clinisorb is an activated charcoal dressing which adsorb toxins removing malodour from the wound Can be cut to size Cost effective |
| 06.04.01.01 | Clinorette® tablets | |
| 04.08.01 | Clobazam | MHRA Advice Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history. |
| 13.04 | Clobetasol Propionate 0.05% Dermovate® | Potency: very potent |
| 13.04 | Clobetasone Butyrate 0.05% cream Eumovate® | Potency: moderate |
| 13.04 | Clobetasone Butyrate 0.05% ointment Eumovate® | Potency: moderate |
| 06.05.01 | Clomifene Citrate |
|
| 04.03.01 | Clomipramine |
|
| 04.08.01 | Clonazepam tablets | MHRA Advice Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history. |
| 02.05.02 | Clonidine Hydrochloride tablets Catapres® | |
| 02.09 | Clopidogrel 75mg tablets | |
| 07.02.02 | Clotrimazole | |
| 12.01.01 | Clotrimazole Canesten® | |
| 13.10.02 | Clotrimazole 1% | |
| 04.02.01 | Clozapine tablets | |
| 13.14.03 | Coal tar BP 10% w/w in YSP | |
| 13.14.03 | Coal tar BP 2% w/w in YSP | |
| 13.14.03 | Coal tar BP 5% w/w in YSP | |
| 13.09 | Coal Tar Extract 5% (Alcoholic) Alphosyl 2 in 1® | Over the counter preparation suitable for self-care/purchase if appropriate |
| 13.05.02 | Coal tar lotion 5% Exorex® | |
| 13.05.02 | Coal Tar Solution 2.5%, Arachis (peanut) Oil extract of Coal Tar 7.5%, Tar 7.5%, Cade Oil 7.5%, Liqiud Paraffin 35% Polytar Emollient® | |
| 13.14.02 | Coal tar solution BP 3.3% w/w and propylene glycol 20% w/w in Synalar® gel | |
| 13.14.02 | Coal tar solution BP 5% w/w in betamethasone valerate 0.025% w/w ointment | |
| 13.14.03 | coal tar solution BP 6% w/w / salicylic acid 2% w/w in emulsifying ointment | |
| 13.14.03 | Coal tar solution BP 6% w/w and salicylic acid 6% w/w in Ung. merck | |
| 02.02.04 | Co-amilofruse (furosemide and amiloride) | Combination products should be avoided, unless compliance is an issue. |
| 05.01.01.03 | Co-Amoxiclav oral presentations |
|
| 05.01.01.03 | Co-Amoxiclav injection | |
| A5.08.08 | Coban, Coban Lite® | Two layer compression system available in full and reduced compression (Coban Lite). Comprises of a latex free foam padding and cohesive bandage. Type of wound product is suitable for Treatment of venous and mixed aetiology leg ulcers Duration dressing remains on wound before changing 1 to 7 days Frequency of dressing change Daily up to weekly dependant on exudate and oedema management. Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Arterial disease Not to be used with other padding or wadding Rationale for inclusion in formulary Two layer compression kit, Once applied the two layers form a band to become a single layer bandage. Bandage technique can be adapted to reduce forefoot oedema (Extra training required) |
| 04.09.01 | Co-Beneldopa | |
| 04.09.01 | Co-Careldopa | |
| 04.09.01 | Co-Careldopa and Entacapone Stalevo® |
|
| 13.14.06 | Coconut oil 25% w/w in emulsifying ointment | |
| 13.06.02 | Co-Cyprindiol 2000/35 | |
| 01.06.02 | Co-danthramer | Capsules 25/200, 75/1000 Suspension 25/200 in 5ml, Strong suspension 75/1000 in 5ml Co-dantramer strong preferred as per palliative care formulary guidance For constipation in terminally ill patients only |
| 01.06.02 | Co-danthrusate | Capsules 50/60 For constipation in terminally ill patients only |
| 01.04.02 | Codeine | Tablets 15mg, 30mg, Syrup 25mg/5ml |
| 04.07.02 | Codeine Phosphate |
|
| 04.07.02 | Codeine Phosphate injection | |
| 10.01.04 | Colchicine | |
| 09.06.04 | Colecalciferol oral | Please see guidance below to support prescribing Please prescribe generically as listed below Oral Capsules or Tablets Colecalciferol 800 unit capsules Colecalciferol 800 unit tablets Colecalciferol 1,000unit capsules Colecalciferol 1,000unit tablets Colecalciferol 3,200unit capsules Colecalciferol 4,000unit tablets Colecalciferol 20,000unit capsules Colecalciferol 25,000unit tablets Colecalciferol 40,000unit capsules Oral Solution Colecalciferol 2,740units/ml oral drops sugar free Colecalciferol 10,000units/ml oral drops sugar free Colecalciferol 10,000units/ml oral solution sugar free Colecalciferol 15,000units/5ml oral solution Colecalciferol 25,000units/1ml oral solution unit dose ampoules sugar free Colecalciferol 50,000units/1ml oral solution unit dose ampoules sugar free Licensed brands currently available (updated March 2017) Aviticol 800 IU Capsules Aviticol 1,000 IU Capsules (Listed in the Drug Tariff) Aviticol 20,000 IU Capsules Desunin 800 IU Tablets (Listed in the Drug Tariff) Desunin 4,000 IU Tablets (Listed in the Drug Tariff) Fultium-D3 800 IU Capsules (Listed in the Drug Tariff) Fultium-D3 3,200 IU Capsules (Listed in the Drug Tariff) Fultium-D3 20,000 IU Capsules (Listed in the Drug Tariff) Fultium-D3 2740 IU/ml oral drops, solution (Listed in the Drug Tariff) InVita D3 800 IU Capsules InVita D3 2,400 IU/ml oral drops, solution InVita D3 25,000 IU oral solution (Listed in the Drug Tariff) InVitaD3 50,000 IU oral solution (Listed in the Drug Tariff) Plenachol 20,000 IU Capsules Plenachol 40,000 IU Capsules (Listed in the Drug Tariff) Stexerol-D3 1,000 IU Tablets (Listed in the Drug Tariff) Stexerol-D3 25,000 IU Tablets (Listed in the Drug Tariff) STRIVIT-D3 800 IU Capsules THORENS 10 000 I.U. /ml oral drops, solution (Listed in the Drug Tariff) THORENS 25 000 I.U. /2.5 ml oral solution |
| 09.05.02.02 | Colestilan BindRen® | |
| 01.09.02 | Colestyramine | Powder |
| 02.12 | Colestyramine sachets | Jaundice and Primary Biliary Cholangitis (PBC) |
| 05.01.07 | Colistimethate injection | |
| 05.01.07 | Colistimethate for nebulisation |
|
| 05.01.07 | Colistimethate inhaler Colobreathe® | |
| 03.13 | Colistimethate sodium Colistin sulfomethate sodium nebulised | Commissioned by NHS England for Cystic Fibrosis only New patients Existing patients (initiated prior to April 2013) |
| 10.03.01 | Collagenase clostridium histolyticum Xiapex® | In line with NICE |
| 01.01.01 | Co-magaldrox | When low sodium content is required. ££ Mucogel is most cost effective brand Use with caution in renal impairment |
| 07.03.01 | Combined Hormonal Contraceptive Patches Evra® | |
| A5.08.07 | Comprilan® | 100 % cotton short stretch compression bandage Type of wound product is suitable for Venous leg ulceration Varicosis Management of chronic oedema Management of primary and secondary lymphoedema Deep venous thrombosis Thrombophlebitis Duration dressing remains on wound before changing 1 to 7 days Frequency of dressing change Dependant on exudate levels if wound present or oedema management. Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Advanced Peripheral arterial occlusive disease Decompensated cardiac insufficiency Septic phlebitis Phlegmasia coerula doleris Rationale for inclusion in formulary Cotton short stretch bandage. Used by lymphoedema nurse specialists |
| 03.04.03 | Conestat Alfa Ruconest® | Hospital Only- NHSE commissioned |
| A5.15 | Conotrane cream | Barrier cream Type of wound product is suitable for Intact skin, not to be applied to a wound. To protect the skin from moisture, irritation and chafing. Frequency of use Application at every episode of hygiene. Apply a thin layer sparingly Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Not to be used in conjunction with containment products for incontinence due to the inclusion of liquid paraffin in the ingredients, which will repel urine/faeces back onto the skin. Any allergy to the listed ingredients Rationale for inclusion in formulary Dermatology approved |
| 13.02.02 | Conotrane® | Over the counter preparation suitable for self-care/purchase if appropriate |
| 07.03.05 | Copper Intra-uterine devices | |
| 09.04 | Corn flour and corn starch |
|
| 05.01.08 | Co-trimoxazole IV infusion | |
| 05.01.08 | Co-trimoxazole oral presentations | |
| A5.08.03 | Cotton Stokinette BP | Sub bandage lining Type of wound product is suitable for To be used under retention and compression bandages Duration dressing remains on wound before changing As required Frequency of dressing change As required Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Not to be used under Coban compression therapy Not to be used under compression hosiery Does not conform to a limb shape. If conformity is required, choose Clinifast Rationale for inclusion in formulary Cost effective choice when conformity to a limb is not required |
| 09.04 | Cow & Gate Pepti-Junior® |
|
| 08.01.05 | Crisantaspase Erwinase® | |
| 08.01.05 | Crizotinib Xalkori® | |
| 13.03 | Crotamiton Eurax® | Over the counter preparation suitable for self-care/purchase if appropriate |
| A5.03.04 | Cutimed ®Sorbact | DACC coated dressings providing antimicrobial properties, available in a pad, gel, gel sheet, ribbon, round swab and rectangular swab Type of wound product is suitable for Colonised or clinically infected moist wound, suitable for any wound type Duration dressing remains on wound before changing 1-3 days Frequency of dressing change 1-3 days dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Do not use in combination with oils and creams Known hypersensitivity to ingredients Not for dry wound Not for heavily exuding wounds Rationale for inclusion in formulary Alternative to available antimicrobials |
| A5.02.02 | C-View Post-Op | Vapour-permeable adhesive film with absorbent pad Type of wound product is suitable for Dry non infected wounds, low exuding wounds, minor burns, protection of intact skin, protection of newly epithelialized wounds Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change Up to 7 days Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Clinically infected wounds, bleeding or exuding wounds Rationale for inclusion in formulary Protection of intact skin, low exuding wounds. Waterproof |
| 04.06 | Cyclizine | |
| 11.05 | Cyclopentolate Hydrochloride 0.5% eye drops | |
| 11.05 | Cyclopentolate Hydrochloride 1% eye drops | |
| 11.05 | Cyclopentolate Hydrochloride single use Minims® | |
| 08.01.01 | Cyclophosphamide Tablets | |
| 05.01.09 | Cycloserine | |
| 06.04.02 | Cyproterone Acetate | |
| 08.03.04.02 | Cyproterone Acetate | |
| 09.04 | Cystine500® |
|
| 08.01.03 | Cytarabine–daunorubicin liposomal Vyxeos® | In line with NICE |
| 02.08.02 | Dabigatran | Following diagnosis of AF- use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD. RICaD: Dabigatran in AF Use following Hip and Knee surgery- full course of treatment supplied on discharge. For the treatment and secondary prevention of DVT and/or PE - use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD. RICaD: Dabigatran in DVT / PE |
| 08.01.05 | Dabrafenib with Trametinib | In line with NICE |
| 05.03.03.02 | Daclatasvir Daklinza® | In line with NICE |
| 09.04 | Dalia |
|
| 02.08.01 | Danaparoid Orgaran® | |
| 06.07.02 | Danazol | |
| 10.02.02 | Dantrolene capsules | |
| 01.06.02 | Dantron | For constipation in terminally ill patients only |
| 06.01.02.03 | Dapagliflozin Forxiga▼® | SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis In line with NICE |
| 05.01.10 | Dapsone | |
| 05.01.07 | Daptomycin injection | |
| 08.01.05 | Daratumumab Darzalex ® | In line with NICE |
| 09.01.03 | Darbepoetin Alfa Aranesp® | |
| 05.03.01 | Darunavir Prezista® | |
| 08.01.05 | Dasatinib Sprycel® | In line with NICE |
| A5.05.03 | Debrisoft® | £££ Debridement pad to cleanse and debride wounds. Type of wound product is suitable for Acute or chronic wounds with surface debris eg pressure ulcers, leg ulcers, diabetic foot ulcers Hyperkeratosis Duration dressing remains on wound before changing Not applicable Frequency of dressing change At each dressing change or as required Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Known sensitivity to polyester Heavy slough and necrotic tissue may require autolytic debridement to soften prior to use Thick hyperkeratosis may take more than one treatment Must be wet with clean warm water prior to use Do not get an emollient on the pad as this blocks the monofilaments Rationale for inclusion in formulary Lifts debris, superficial slough and exudate without damaging new granulation or epithelial cells Removes biofilms Lifts hyperkeratosis and dry flaking skin peri-wound Recommended by NICE Treatment well tolerated Convenient, easy to use, disposable single use pad |
| 09.01.03 | Deferasirox Exjade® | |
| 09.01.03 | Deferiprone Ferriprox® | |
| 08.03.04.02 | Degarelix | to access |
| 05.01.03 | Demeclocycline capsules | |
| 06.05.02 | Demeclocycline capsules | |
| 06.06.02 | Denosumab XGEVA® | |
| 06.06.02 | Denosumab Prolia® | |
| 13.08.02 | Dermablend® | |
| 13.10.05 | Dermabond ProPen® | Hospital only |
| 13.08.02 | Dermacolor® | |
| A5.13 | Dermatonics Once Heel balm | Cream containing 25% urea Type of wound product is suitable for To moisturise dry skin on the soles of feet For use on adults and children over 12 years of age Frequency of use Reapply daily Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Allergy or hypersensitivity to any of the ingredients, contains beeswax and lanolin Not to be used on children under 12 Rationale for inclusion in formulary Treatment of dry skin conditions of the foot. Dermatology approved |
| 13.02.01 | Dermatonics Once Heel Balm® | specialist recommendation for epidermolysis bullosa Over the counter preparation suitable for self-care/purchase if appropriate |
| A5.13 | Dermol 500 Lotion | Emollient lotion containing an antimicrobial Type of wound product is suitable for For dry and pruritic skin conditions including eczema and dermatitis. Can be applied to skin as an emollient or used as a soap substitute Frequency of use Reapply daily Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Allergy or hypersensitivity to any of the ingredients, contains benzalkonium chloride, 0.1%, chlorhexidine hydrochloride 0.1%, liquid paraffin, isopropyl myristate. Should not be used unless infection is present or is a frequent complication Rationale for inclusion in formulary Treatment of dry skin requiring antimicrobial properties Dermatology approved |
| 13.02.01 | Dermol 500 lotion ® | short term use only Over the counter preparation suitable for self-care/purchase if appropriate |
| 13.02.01.01 | Dermol 600® | Over the counter preparation suitable for self-care/purchase if appropriate |
| 09.01.03 | Desferrioxamine Mesilate | |
| 06.05.02 | Desmopressin | |
| 07.03.02.01 | Desogestrel 75mcg | |
| 09.04.01 | Desserts | Important protein-free foods to provide important energy, assist dietary adherence and provide variety when natural protein tolerance is very limited. Necessary for children and adults with inborn errors of protein metabolism who tolerate very little natural protein. |
| 06.03.02 | Dexamethasone | |
| 11.04.01 | Dexamethasone 0.1% eye drops Maxidex® | |
| 11.04.01 | Dexamethasone 0.1% eye drops Single dose units | |
| 11.04.01 | Dexamethasone 700mcg intravitreal implant Ozurdex® | |
| 04.06 | Dexamethasone injection | |
| 06.03.02 | Dexamethasone phosphate injection | |
| 04.06 | Dexamethasone tablets | |
| 12.01.01 | Dexamethasone with Antibacterial Sofradex® | |
| 11.04.01 | Dexamethasone with Antibacterials Tobradex® | |
| 12.01.01 | Dexamethasone with neomycin and glacial acetic acid Otomize® | |
| 11.04.01 | Dexamethasone with Neomycin and Polymyxin B sulphate Maxitrol® | |
| 04.04 | Dexamfetamine | Please note that commissioning discussion is underway. However the present status is as follows:- Birmingham CrossCity CCG, Birmingham South Central CCG, Sandwell & West Birmingham CCG Supported with an ESCA- Solihull CCG |
| 09.04 | Dialamine® |
|
| 04.07.02 | Diamorphine salts | |
| 04.01.02 | Diazepam | |
| 04.01.02 | Diazepam | |
| 04.10.01 | Diazepam | |
| 10.02.02 | Diazepam | |
| 04.01.01 | Diazepam liquid | Inpatient use and prison settings only |
| 04.08.02 | Diazepam rectal tubes | |
| 10.01.01 | Diclofenac | |
| 10.01.01 | Diclofenac | |
| 11.08.02 | Diclofenac Voltarol® Ophtha SDU | |
| 11.08.02 | Diclofenac Sodium Voltarol® Ophtha multidose | |
| 13.08.01 | Diclofenac sodium 3% gel | |
| 05.03.01 | Didanosine Videx® | |
| 08.03.01 | Diethylstilbestrol | ££££ |
| 13.04 | Diflucortolone Valerate 0.3% oily cream | Potency: very potent |
| 02.01.01 | Digoxin Elixir | Use only if still symptomatic despite optimal treatment of HF with atrial fibrillation. Take extra caution in the elderly who may be more susceptible to digitalis toxicity. |
| 02.01.01 | Digoxin Injection | |
| 02.01.01 | Digoxin specific antibody fragments Digifab® | |
| 02.01.01 | Digoxin Tablets | Use only if still symptomatic despite optimal treatment of HF with atrial fibrillation. Take extra caution in the elderly who may be more susceptible to digitalis toxicity. |
| 04.07.02 | Dihydrocodeine | |
| 05.04.02 | Diloxanide Furoate Diloxanide® | |
| 02.06.02 | Diltiazem | 60mg tablets - FIRST LINE. For administration three times a day. No requirement for brand name prescribing. Modified- release formulations should be prescribed by brand name. Brand rationalisation- APC preferred brands:(in alphabetical order, does not suggest order of preference) |
| 01.07.04 | Diltiazem Cream 2% | Cream ££££ Unlicensed - for use only in patients intolerant of or unresponsive to GTN ointment Store in fridge One tube will last a month if used as 2cm application TWICE DAILY |
| 08.02.04 | Dimethyl fumarate Tecfidera® | |
| 13.05.03 | Dimethyl fumarate Skilarence® | |
| 07.04.04 | DIMETHYL SULPHOXIDE Bladder Instillation 50% | Hospital only |
| 13.10.04 | Dimeticone | Over the counter preparation suitable for self-care/purchase if appropriate |
| 07.01.01 | Dinoprostone | |
| 07.01.01.01 | Dinoprostone Prostin E2® | |
| 08.02.03 | Dinutuximab | In line with NICE |
| 13.14.07 | Diphenylcyclopropenone in acetone 0.00001-6.0% w/v | |
| 02.09 | Dipyridamole MR capsules Persantin® Retard | |
| 02.09 | Dipyridamole tablets | |
| 06.06.02 | Disodium Pamidronate | |
| 02.03.02 | Disopyramide capsules | |
| 02.03.02 | Disopyramide injection | |
| 04.10.01 | Disulfiram Antabuse® | |
| 13.05.02 | Dithranol Dithrocream® | |
| 13.14.05 | Dithranol in Lassar’s paste 0.1% w/w | |
| 13.14.05 | Dithranol in Lassar’s paste 0.5% w/w | |
| 13.14.05 | Dithranol in Lassar’s paste 1% w/w | |
| 13.14.05 | Dithranol in Lassar’s paste 10% w/w | |
| 13.14.05 | Dithranol in Lassar’s paste 15% w/w | |
| 13.14.05 | Dithranol in Lassar’s paste 2% w/w | |
| 13.14.05 | Dithranol in Lassar’s paste 4% w/w | |
| 13.14.05 | Dithranol in Lassar’s paste 8% w/w | |
| 13.14.05 | Dithranol pomade 0.4% w/w | dithranol 0.4% w/w, salicylic acid 2% w/w, emulsifying wax BP 25% w/w, liquid paraffin to 100% |
| 02.07.01 | Dobutamine | |
| 08.01.05 | Docetaxel | In line with NICE |
| 09.04 | DocOmega® |
|
| 01.06.02 | Docusate Sodium | Capsules 100mg, Liquid 50mg/5ml - Solution is utterly unpalatable - only fit for use down tubes) - Probably acts as a softening laxative as well as a stimulant - Time to effect is approximately 24 to 48 hours |
| 01.02 | Domperidone | Second line Domperidone is no longer recommended for the management of heartburn, bloating and stomach discomfort. See the link below for more information |
| 04.06 | Domperidone | |
| 04.11 | Donepezil | The APC's view is that on clinical grounds, the status of these drugs for dementia should be amber, with a framework in place in primary care before transfer. HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED. |
| 02.07.01 | Dopamine | |
| 03.07 | Dornase Alfa Pulmozyme® | Commissioned by NHS England for Cystic Fibrosis only New patients For existing patients (initiated pre April 2013)
|
| 11.06 | Dorzolamide 2% | |
| 11.06 | Dorzolamide 2% with Timolol 0.5% | |
| 11.06 | Dorzolamide 2% with Timolol 0.5% SDU Eye Drops Cosopt® | |
| 11.06 | Dorzolamide 2% eye drops (SDU) Trusopt® | |
| 13.02.01 | DoubleBase Gel ® | Over the counter preparation suitable for self-care/purchase if appropriate |
| 03.05.01 | Doxapram Dopram® | Hospital only |
| 02.05.04 | Doxazosin tablets | Plain tablets  Modified release tablets are non- formulary |
| 07.04.01 | Doxazosin tablets | Plain tablets only
|
| 13.03 | Doxepin Hcl cream Xepin ® |
|
| 08.01.02 | Doxorubicin Hydrochloride Lipid formulation | |
| 05.01.03 | Doxycycline oral | |
| 05.01.03 | Doxycycline injection | |
| 13.06.02 | Doxycycline | Please refer to Antimicrobial guidelines |
| 02.03.02 | Dronedarone tablets Multaq® | To be used in line with NICE guidance |
| 03.01.05 | Drug Delivery Device Haleraid® | |
| 03.01.05 | Drug Delivery Devices | All spacer devices |
| 06.04.01.01 | Duavive® |
|
| 06.01.02.03 | Dulaglutide Trulicity® |
|
| 04.03.04 | Duloxetine Cymbalta® | |
| 04.07.03 | Duloxetine Cymbalta® | |
| 07.04.02 | Duloxetine | |
| 09.04 | Duocal® Super Soluble |
|
| A5.02.04 | Duoderm range of dressings | The adhesive layer forms a cohesive gel when in contact with wound exudate Available as Extra thin or Signal (Bordered) Type of wound product is suitable for Dry to lightly exuding wounds Non infected Acute or Chronic wounds Duration dressing remains on wound before changing Up to 7 days maximum Frequency of dressing change 3-7 days Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Not suitable for infected wounds, full thickness burns or wounds with exposed bone, muscle or tendon or wounds that are likely to macerate, particularly on plantar surface of foot Not for diabetic foot ulcers Not for ischaemic wounds Known product or component sensitivity Rationale for inclusion in formulary Conformable, waterproof, aids autolysis. Protect surrounding skin , reduced risk of blistering. Cost effective |
| 08.01.05 | Dupilumab | In line with NICE |
| 06.04.02 | Dutasteride Avodart® |
|
| 09.04 | EAA® Supplement |
|
| A5.11 | Easy-Slide | Application aid for open toe compression hosiery garments |
| A5.01.02 | Eclypse | Approved June 2018 to replace Flivasorb® |
| 11.03.02 | Econazole 1% eye drops | |
| 07.02.02 | Econazole pessaries Gyno-Pevaryl® | |
| 02.08.02 | Edoxaban  |
For treating and for preventing recurrent DVT and PE- use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD RICaD: Edoxaban in DVT/PE Following diagnosis of AF- use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD RICaD: Edoxaban in AF |
| 10.02.01 | Edrophonium Chloride | Hospital only |
| 05.03.01 | Efavirenz Sustiva® | |
| 09.04.02 | Elemental 028®Extra |
|
| 09.04.02 | Elemental 028®Extra |
|
| 09.08.01 | Eliglustat Cerdelga® | In line with NICE Highly Specialised Technology guidance- NHSE commissioned |
| 06.04.01.01 | Elleste Solo MX® Patch |
|
| 06.04.01.01 | Elleste Solo® |
|
| 06.04.01.01 | Elleste-Duet Conti® tablets | |
| 06.04.01.01 | Elleste-Duet® tablets (sequential) | |
| 09.01.04 | Eltrombopag Revolade® | |
| 01.05 | Eluxadoline | |
| 06.01.02.03 | Empagliflozin Jardiance▼® | SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis In line with NICE |
| 05.03.01 | Emtricitabine Emtriva® | |
| A5.14 | Emulsifying Ointment | Emollient ointment containing emulsifying wax, white soft paraffin and liquid paraffin Type of wound product is suitable for For treatment of dry skin conditions Frequency of use Daily Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Allergy or hypersensitivity to any of the ingredients Rationale for inclusion in formulary Treatment of dry skin Dermatology approved |
| 13.02.01 | Emulsifying Ointment BP | Over the counter preparation suitable for self-care/purchase if appropriate |
| 02.05.05.01 | Enalapril tablets | For existing patients only. |
| 08.01.05 | Encorafenib with binimetinib | In line with NICE |
| 09.04 | Energivit® |
|
| 02.08.01 | Enoxaparin | Single use in suspected DVT For all other indications. The APC's view is that on clinical grounds, the status for certain indications approved by APC should be amber, supported by an ESCA. HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED.(ESCAs to be developed). |
| 02.01.02 | Enoximone Perfan® | |
| 09.04 | Enshake® |
|
| 09.04.02 | Ensure®Twocal |
|
| 04.09.01 | Entacapone |
|
| 05.03.03 | Entecavir Baraclude® | |
| 08.03.04.02 | Enzalutamide Xtandi® | |
| 13.14.07 | Eosin solution 2% w/v | |
| A5.14 | Epaderm ®Ointment | Emollient ointment containing liquid paraffin, yellow soft paraffin and emulsifying wax Type of wound product is suitable for For use on all dry skin conditions and with dry or wet wrapping techniques Frequency of use Daily or more frequently if required Caution/contraindications Non listed Rationale for inclusion in formulary Treatment of dry skin conditions. Dermatology approved |
| 13.02.01 | Epaderm® ointment | Over the counter preparation suitable for self-care/purchase if appropriate |
| 02.07.02 | Ephedrine | |
| 12.02.02 | Ephedrine nose drops | |
| 13.02.01 | Epimax ® cream | |
| 02.02.03 | Eplerenone tablets | |
| 09.01.03 | Epoetin beta NeoRecormon® | |
| 02.08.01 | Epoprostenol Flolan® | |
| 03.07 | Erdosteine | |
| 09.06.04 | Ergocalciferol | |
| 07.01.01 | Ergometrine Maleate | |
| 07.01.01 | Ergometrine Maleate and Oxytocin Syntometrine® | |
| 08.01.05 | Eribulin Halaven® | |
| 08.01.05 | Erlotinib Tarceva® | |
| 05.01.02.02 | Ertapenem | |
| 06.01.02.03 | Ertugliflozin Steglatro® | In line with NICE |
| 05.01.05 | Erythromycin tablets | |
| 05.01.05 | Erythromycin Ethyl succinate oral suspension | |
| 05.01.05 | Erythromycin Lactobionate Injection | |
| 04.08.01 | Eslicarbazepine |
|
| 02.04 | Esmolol injection | |
| 01.03.05 | Esomeprazole Injection |
|
| 06.04.01.01 | Estraderm MX® Patch | |
| 07.03.01 | Estradiol/dienogest Qlaira® | |
| 06.04.01.01 | Estradot® |
|
| 08.01.01 | Estramustine Phosphate capsules | |
| 06.04.01.01 | Estriol® 0.01% | |
| 02.11 | Etamsylate Dicynene® | |
| 10.01.03 | Etanercept Enbrel® | Hospital only |
| 13.05.03 | Etanercept | |
| 09.05.01.02 | Etelcalcetide Parsabiv® | In line with NICE, NHSE commissioned Black Triangle |
| 05.01.09 | Ethambutol | Ethambutol liquid 400mg in 5ml (unlicensed) |
| 07.03.01 | Ethinylestradiol / levonorgestrel phased pill TriRegol® | |
| 07.03.01 | Ethinylestradiol 20 mcg / norethisterone 1mg Loestrin 20® | |
| 07.03.01 | Ethinylestradiol 20mcg / desogestrel 150mcg Gedarel®20/150/ Lestramyl®20/150 | |
| 07.03.01 | Ethinylestradiol 20mcg / gestodene 75 mcg Millinette®20/75 | |
| 07.03.01 | Ethinylestradiol 30 mcg / drospirenone 3 mg | Brands approved by APC: |
| 07.03.01 | Ethinylestradiol 30mcg / desogestrel 150mcg Gedarel®30/150, Lestramyl®30/150 | |
| 07.03.01 | Ethinylestradiol 30mcg / gestodene 75 mcg Millinette®30/75 | |
| 07.03.01 | Ethinylestradiol 30mcg / levonorgestrel 150mcg | |
| 07.03.01 | Ethinylestradiol 30mcg / levonorgestrel 150mcg Microgynon 30 ED ® | |
| 07.03.01 | Ethinylestradiol 35 mcg / noresthisterone 500mcg Brevinor® | |
| 07.03.01 | Ethinylestradiol 35 mcg / norgestimate 250 mcg Lizinna® | |
| 06.04.01.01 | Ethinylestradiol tablets |
|
| 07.03.01 | Ethinylestradiol/ Norethisterone Synphase® | |
| 04.08.01 | Ethosuximide capsules | MHRA Advice When prescribing for epilepsy, the potential for clinically relevant differences to exist between different manufacturers’ products is considered to be extremely low. However, consider other patient/carer-related factors, such as negative perceptions about alternative products and/or other issues related to the patient such co-morbid autism, mental health issues, or learning disability. |
| 07.03.02.02 | Etonorgestrel 68mg implant Nexplanon® | |
| 05.03.01 | Etravirine Intelence® | |
| 13.02.01 | Eucerin® Intensive lotion 10%urea | Over the counter preparation suitable for self-care/purchase if appropriate |
| 08.01.05 | Everolimus Afinitor® | In line with NICE Hospital only-NHSE commissioned |
| 02.11 | Evicel ® | |
| 02.12 | Evolocumab Repatha® | To be used in line with NICE TA 394 |
| 06.04.01.01 | Evorel Conti® patch | |
| 06.04.01.01 | Evorel Sequi® patch | |
| 06.04.01.01 | Evorel® |
|
| 08.03.04.01 | Exemestane | |
| 02.12 | Ezetimibe Ezetrol® | in line with NICE |
| 02.11 | Factor VIIa (Recombinant) Eptacog alfa | |
| 05.03.02.01 | Famciclovir | |
| 10.01.04 | Febuxostat Adenuric® | |
| 02.06.02 | Felodipine | Brand rationalisation - APC preferred brands:- |
| 06.04.01.01 | Femoston Conti® | |
| 06.04.01.01 | Femoston® (sequential) | |
| 06.04.01.01 | Femseven Conti® patch | |
| 06.04.01.01 | Femseven Sequi® patch |
|
| 02.12 | Fenofibrate | |
| 04.07.02 | Fentanyl lozenges | |
| 04.07.02 | Fentanyl Nasal Spray | |
| 04.07.02 | Fentanyl patches | |
| 04.07.02 | Fentanyl sublingual tablets | |
| 09.01.01.02 | Ferric Carboxymaltose Ferinject® | Hospital only |
| 09.01.01.01 | Ferric maltol Feraccru® |
|
| 09.01.01.01 | Ferrous Fumarate liquid Fersamal® | |
| 09.01.01.01 | Ferrous Fumarate tablets | |
| 09.01.01.01 | Ferrous Gluconate | |
| 09.01.01.01 | Ferrous Sulphate | |
| 03.04.01 | Fexofenadine | Second Line |
| 05.01.07 | Fidaxomicin | |
| 09.01.06 | Filgrastim | |
| 06.04.02 | Finasteride 1mg tablets |
|
| 06.04.02 | Finasteride 5mg tablets | |
| 13.09 | Finasteride Propecia® |
Black listed in NHS primary care |
| 08.02.04 | Fingolimod | |
| A5.03.04 | Flaminal ® Forte Gel | Alginate gel. Moderate to heavily exuding wounds. Contains antimicrobial enzymes. Type of wound product is suitable for Colonised wound bed. More suited to sloughy wounds. Can be used on all wound types Useful for cavity wounds and sinus’s Requires a secondary dressing Duration dressing remains on wound before changing 1-7 days Frequency of dressing change 1-7 days dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Sensitivity to alginate dressings or polyethylene glycol Full thickness burns Rationale for inclusion in formulary 1st line antimicrobial in paediatrics Consider as first line product if signs of colonisation or clinical infection Does not cause cellular damage |
| A5.03.04 | Flaminal ®Hydro Gel | Alginate gel. Low to moderate exuding wounds. Contains antimicrobial enzymes Type of wound product is suitable for Colonised wound bed. More suited to sloughy wounds. Can be used on all wound types Useful for cavity wounds and sinus’s Requires a secondary dressing Duration dressing remains on wound before changing 1-7 days Frequency of dressing change 1-7 days dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Sensitivity to alginate dressings or polyethylene glycol Full thickness burns Rationale for inclusion in formulary 1st line antimicrobial in paediatrics Consider as first line product if signs of colonisation or clinical infection Does not cause cellular damage |
| 06.01.06 | Flash glucose monitoring system FreeStyle Libre® | |
| 07.03.04 | Flat spring diaphragm | |
| 09.04 | FlavourPac® |
|
| 02.03.02 | Flecainide injection | |
| 02.03.02 | Flecainide tablets | |
| 01.06.05 | Fleet Phospho-soda® | Oral solution |
| 09.04.01 | Flour mixes and egg substitutes | Essential protein-free basic products. Necessary for children and adults with inborn errors of protein metabolism who tolerate very little natural protein. 1 ordinary egg = 6g protein. 100g flour = 10g protein. |
| 13.04 | Flucinolone Acetonide 0.0025% Synalar 1 in 10 Dilution® | Paeds use only Potency :Mild February 2017: aware of unavailability, use alternative mild potency preparation. |
| 13.04 | Flucinolone Acetonide 0.025% Synalar Gel® | £££ Potency:Potent |
| 05.01.01.02 | Flucloxacillin injection | |
| 05.01.01.02 | Flucloxacillin oral presentations | As per antimicrobial guidelines |
| 05.02 | Fluconazole | |
| 07.02.02 | Fluconazole 150mg oral capsule | |
| 05.02 | Flucytosine | |
| 08.01.03 | Fludarabine Phosphate | |
| 06.03.01 | Fludrocortisone | |
| 13.04 | Fludroxycortide 7.5cm x 200cm tape previously known as Haelan® | ££ Potency: moderate |
| A5.16 | Fludroxycortide tape | Adhesive, waterproof, occlusive tape impregnated with 4mg/cm2 fludroxycortide (topical steroid) Type of wound product is suitable for Chronic overgranulation, non acute or weeping. Duration dressing remains on wound before changing Cut the tape to size. Apply for 12 hours at a time, remove and discard. Apply to clean, dry skin that is shorn of any hair. Frequency of dressing change Apply daily for 12 hours at a time. Maximum treatment time 7 days. Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Chicken pox Tuberculosis of the skin Hypersensitivity to any components in the tape (steroid fludroxycortide) Facial rosacea Acne vulgaris Perioral dermatitis Perianal and genital pruritis Dermatoses in infants Dermatitis napkin eruption Bacterial, viral and fungal infections Keep away from the eyes Avoid prolonged use on the face Not for untreated bacterial, fungal or viral skin lesions Rationale for inclusion in formulary Treatment of overgranulation |
| 12.01.01 | Flumetasone 0.02% with Clioquinol 1% Locorten-Vioform® | |
| 04.07.04.02 | Flunarizine | Unlicensed medicine |
| 13.04 | fluocinolone acetonide 0.025% with clioquinol 3% Synalar C® | Potency: potent |
| 11.04.01 | Fluocinolone intravitreal implant Iluvien® | |
| 11.04.01 | Fluorometholone 0.1% FML® | |
| 11.99.99.99 | Fluorouracil | |
| 13.08.01 | Fluorouracil Efudix® | |
| 13.08.01 | fluorouracil 0.5%, salicylic acid 10% Actikerall® | For hyperkeratotic lesions |
| 04.03.03 | Fluoxetine capsules | |
| 04.03.03 | Fluoxetine liquid | |
| 04.02.02 | Flupentixol Decanoate | The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer. HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED. |
| 04.02.01 | Flupentixol tablets | |
| 04.02.02 | Fluphenazine Decanoate Modecate® | The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer.
|
| 08.03.04.02 | Flutamide | |
| 03.02 | Fluticasone and formoterol Flutiform® | |
| 03.02 | Fluticasone and salmeterol Seretide® | For paediatric use ONLY (i.e. up to 18 years of age) |
| 12.02.01 | Fluticasone furoate Avamys® | |
| 03.02 | Fluticasone furoate & vilanterol Relvar Ellipta® | |
| 03.02 | Fluticasone inhalers | For paediatric use ONLY (i.e. up to 18 years of age) Fluticasone Evohaler 50, Fluticasone Accuhaler 50,100
|
| 03.02 | Fluticasone nebules | |
| 12.02.01 | Fluticasone Propionate Flixonase Nasule® | |
| 03.02.03 | Fluticasone/vilanterol/umeclidinium Trelegy Ellipta® | COPD Appendix 4 : Criteria for triple therapy and for triple inhaler use in COPD
|
| 02.12 | Fluvastatin capsules | |
| 09.01.02 | Folic Acid | Tablets SF solution- Lexpec® |
| 02.08.01 | Fondaparinux Arixtra® | Hospital only |
| 09.04 | Food First | Where clinically appropriate encourage a nutrient dense food and fluid intake for patients at risk of malnutrition. |
| 09.04.02 | Food First | Where clinically appropriate encourage a nutrient dense food and fluid intake for patients at risk of malnutrition. |
| 09.04 | Foodlink® Complete |
|
| 09.04 | Foodlink® Complete with Fibre |
|
| 09.04 | Forceval caps and soluble tabs |
|
| 03.01.01.01 | Formoterol | |
| 09.04 | Fortijuce® |
|
| 09.04 | Fortini® |
|
| 09.04.02 | Fortini® 1.0 Multi Fibre | Child under 12 years |
| 09.04 | Fortini® Compact Multifibre |
|
| 09.04 | Fortini® Creamy Fruit |
|
| 09.04 | Fortini® Multifibre |
|
| 09.04 | Fortini® Smoothie Multifibre |
|
| 09.04 | Fortisip® 2kcal |
|
| 09.04 | Fortisip® Bottle |
|
| 09.04 | Fortisip® Compact |
|
| 09.04 | Fortisip® Compact Fibre |
|
| 09.04 | Fortisip® Compact Protein |
|
| 09.04 | Fortisip® Yogurt Style |
|
| 05.03.01 | Fosamprenavir Telzir® | |
| 05.03.02.02 | Foscarnet Sodium Foscavir® | |
| 05.01.13 | Fosfomycin sachets |
|
| 05.01.13 | Fosfomycin Capsules | Second line treatment if high risk of resistance. In line with antimicrobial guidelines |
| 02.11 | Fresh Frozen Plasma | |
| 09.04 | Fresubin® 2kcal |
|
| 09.04 | Fresubin® 2kcal Fibre Drink |
|
| 09.04 | Fresubin® Juicy Drink |
|
| 09.04 | Fresubin® Thickened |
|
| 09.04 | Fresubin® YOcreme |
|
| 09.04.02 | Fresubin®HP Energy |
|
| 09.04.02 | Fresubin®HP Energy Fibre |
|
| 09.04 | Fructose |
|
| 09.06.07 | FruitiVits® |
|
| 02.02.02 | Furosemide | |
| 11.03.01 | Fusidic Acid 1% | £££ |
| 13.10.01.02 | Fusidic Acid 2% | |
| 09.04 | GA Amino 5 |
|
| 09.04 | GA Anamix Junior |
|
| 09.04 | GA Express 15 (not ACBS approved) |
|
| 09.04 | GA Gel® |
|
| 09.04 | GA1 Anamix® Infant |
|
| 04.07.03 | Gabapentin |
Schedule 3 Controlled Drug as of 01/04/2019 |
| 04.08.01 | Gabapentin |
Schedule 3 Controlled Drug as of 01/04/2019 |
| 09.04 | Galactomin 17® |
|
| 09.04 | Galactomin 19® |
|
| 04.11 | Galantamine | The APC's view is that on clinical grounds, the status of these drugs for dementia should be amber, with a framework in place in primary care before transfer. HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED. |
| A5.05.01 | Gamgee | Sterile or non sterile highly absorbent cotton wool enclosed in an absorbent cotton cover Type of wound product is suitable for Full thickness burns Can be cut to required size Secondary dressing Duration dressing remains on wound before changing Dependent on exudate levels Frequency of dressing change Dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Not to be used as a primary dressing Only to be used in UHB burns unit Rationale for inclusion in formulary UHB burns unit only |
| 05.03.02.02 | Ganciclovir Cymevene® | |
| 11.03.03 | Ganciclovir 0.15% ophthalmic gel Virgan® | |
| A5.07.02 | gauze swabs, non-woven swabs | 7.5cm x 7.5cm only Type of wound product is suitable for Cleansing wounds via aseptic technique Duration dressing remains on wound before changing N/A Frequency of dressing change N/A Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Not to be applied to a wound as a dressing Rationale for inclusion in formulary Necessity for wound cleansing Cost effective Included in Sterile wound packs or used to supplement sterile packs |
| 01.01.02 | Gaviscon Infant | Oral powder |
| 08.01.05 | Gefitinib Iressa® | |
| 09.02.02.02 | Gelatin Gelofusine® | For Endoscopy use only |
| 12.03.01 | Gelclair® | |
| 08.01.03 | Gemcitabine Gemzar® | |
| 07.01.01 | Gemeprost | |
| 08.02.03 | Gemtuzumab Mylotarg® | In line with NICE |
| 03.13 | Gentamicin | Hospital only |
| 05.01.04 | Gentamicin | |
| 11.03.01 | Gentamicin 0.3% eye drops | |
| 12.01.01 | Gentamicin ear drops Genticin® | |
| 06.04.01.01 | Gestone® injection |
|
| 05.03.03.02 | Glecaprevir–pibrentasvir Maviret® | In line with NICE
|
| 06.01.02.01 | Glibenclamide |
|
| 06.01.02.01 | Gliclazide | |
| 06.01.02.01 | Gliclazide M/R | |
| 06.01.04 | Glucagon GlucaGen® HypoKit | |
| 06.01.04 | GlucoGel® | |
| 09.04 | Glucose |
|
| 13.07 | Glutaraldehyde 10% solution | Over the counter preparation suitable for self-care/purchase if appropriate |
| 09.04.01 | Gluten free foods | Department of Health and Social Care (DHSC) guidance –
Follow Coeliac UK prescribing guidance for monthly quantities (based on age) |
| 01.06.02 | Glycerol (Glycerin) | Suppository |
| 01.07.04 | Glyceryl Trinitrate 0.4% Rectogesic® | Ointment |
| 02.06.01 | Glyceryl Trinitrate Injection | Secondary Care use only |
| 02.06.01 | Glyceryl Trinitrate MR Bucaal Tabletsq | |
| 02.06.01 | Glyceryl Trinitrate patches | |
| 02.06.01 | Glyceryl Trinitrate SL spray and SL tablets | |
| 07.04.04 | Glycine | Hospital only |
| 13.14.07 | Glycopyrrolate 0.05% w/v in water | |
| 13.14.07 | Glycopyrrolate 2% w/w in cetomacrogol cream | |
| 03.01.02 | Glycopyrronium Seebri breezhaler® | |
| 13.12 | Glycopyrronium |
|
| 04.12 | Glycopyrronium bromide Sialanar® | |
| 03.01.04 | Glycopyrronium/ indacaterol inhaler Ultibro Breezhaler® | |
| 09.04 | Glycosade® |
|
| 09.04 | Glytactin Bettermilk 15 |
|
| 09.04 | Glytactin Bettermilk RTD 15 (original and chocolate) |
|
| 10.01.03 | Golimumab Simponi® | Hospital only |
| 06.07.02 | Goserelin | |
| 06.07.02 | Goserelin | |
| 08.03.04.02 | Goserelin Zoladex® | |
| 08.03.04.02 | Goserelin Zoladex® LA | |
| A5.09.01 | Graduated compression hosiery | Based on assessment |
| 04.06 | Granisetron tablets | |
| 04.06 | Granisetron transdermal patch Sancuso® | |
| A5.02.04 | Granuflex | Type of wound product is suitable for Hyperkeratosis, granulating wounds, forms cohesive gel on contact with exudate Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change 3-7 days Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Known sensitivity to ingredients - contains pectin and gelatine Not for diabetic foot ulcers or ischaemic wounds Not for infected wounds Rationale for inclusion in formulary Comformable waterproof dressing, aids rehydration. Reduces and softens hyperkeratosis |
| 03.04.02 | Grass and Tree Pollen Extract Pollinex® | |
| 03.04.02 | Grass pollen extract Grazax® | RICaD: Grazax |
| 09.04 | GTO oil |
|
| 04.04 | Guanfacine Intuniv® | for the treatment of ADHD in children and adolescents 6-17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. |
| 13.05.03 | Guselkumab Tremfya ® | Use in line with NICE |
| 14.04 | Haemophilus influenzae type B Combined Vaccine Menitorix® | |
| 01.07.01 | Haemorrhoid relief ointment | Anusol® - other brands also available |
| 01.07.01 | Haemorrhoid relief suppositories | Anusol® - other brands also available |
| 04.02.02 | Haloperidol Haldol Decanoate® | The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer. HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED. |
| 04.09.03 | Haloperidol | |
| 04.02.01 | Haloperidol (oral) | |
| 04.02.01 | Haloperidol injection |
|
| 09.04 | HCU Anamix® Infant |
|
| 09.04 | HCU Cooler® 10 |
|
| 09.04 | HCU Cooler® 15 |
|
| 09.04 | HCU Cooler® 20 |
|
| 09.04 | HCU Express® 15 |
|
| 09.04 | HCU Express® 20 |
|
| 09.04 | HCU gel® |
|
| 09.04 | HCU Lophlex® LQ 20 |
|
| 09.06.07 | Healthy Start Vitamins | |
| 01.03 | Helicobacter Stool Antigen Test | |
| 01.03 | Helicobacter Urea Breath Test | |
| 02.08.01 | Heparin sodium injection | |
| 13.13 | Heparinoid 0.3% Hirudoid® | |
| 14.04 | Hepatitis A vaccine Single Component Avaxim® | |
| 14.04 | Hepatitis A vaccine Single Component Epaxal® | |
| 14.04 | Hepatitis A vaccine Single Component Havrix Monodose® | |
| 14.04 | Hepatitis A vaccine Single Component Vaqta® Paediatric | |
| 14.04 | Hepatitis A vaccine with Hepatitis B vaccine Twinrix® | |
| 14.05.02 | Hepatitis B immunoglobulin | |
| 14.04 | Hepatitis B vaccine Single Component Engerix B® | |
| 14.04 | Hepatitis B vaccine Single Component Fendrix® | |
| 14.04 | Hepatitis B vaccine Single Component HBvaxPRO® | |
| 13.11.02 | Hibitane Obstetric® | |
| 13.10.05 | Histoacryl® | Hospital only |
| 09.04 | Homemade milkshake | Where clinically appropriate encourage a standardised home-made nutritious |
| 09.04.02 | Homemade milkshake | Where clinically appropriate encourage a standardised home-made nutritious drink equivalent to a standard 1.5 KCal/mL prescribed bottle supplement in terms of calories and protein. |
| 06.05.01 | Human Chorionic Gonadotrophin | |
| 06.05.01 | Human Menopausal Gonadotrophins | |
| 12.04 | Human papilloma virus vaccine Gardasil® | |
| 14.04 | Human papilloma virus vaccine Gardasil® | |
| 14.04 | Human papilloma virus vaccine Cervarix® | |
| 14.04 | Human papilloma virus vaccine Gardasil® | |
| 11.99.99.99 | Hyaluronidase Hyalase® | |
| 02.05.01 | Hydralazine tablets | |
| 01.05.02 | Hydrocortisone Colifoam® | July 2018 - supply problem expected to last until late 2018/early 2019 Foam enema 125mg /metered application |
| 06.03.02 | Hydrocortisone | |
| 13.04 | Hydrocortisone | Potency: mild Hydrocortisone 0.5% cream & ointment Hydrocortisone 1% cream & ointment |
| 13.04 | Hydrocortisone 0.25% Crotamiton 10% Eurax-Hydrocortisone® | Potency: mild Use post scabies once infection has cleared but itch remains present |
| 13.04 | Hydrocortisone 0.5% ,chlorhexidine HCl 1% & nystatin Nystaform-HC® | Potency: mild Paeds use only Replacement for discontinued Vioform HC |
| 13.04 | Hydrocortisone 1% with Clotrimazole 1% Canesten HC® | Potency: mild |
| 13.04 | Hydrocortisone 1% with Miconazole Nitrate 2% Daktacort Cream® | Potency: mild |
| 12.03.01 | Hydrocortisone 2.5mg buccal tablets | |
| 10.01.02.02 | Hydrocortisone acetate Hydrocortistab® | |
| 13.04 | Hydrocortisone Acetate 1% with Fusidic Acid 2% Fucidin H Cream® | Potency: mild |
| 12.01.01 | Hydrocortisone Acetate 1% with Gentamicin 0.3% Gentisone® HC | |
| 13.04 | Hydrocortisone Butyrate Locoid ® | Potency: potent Cream Lipocream Ointment Scalp lotion |
| 06.03.02 | Hydrocortisone sodium succinate Solu-Cortef® | |
| A5.02.02 | Hydrofilm | Vapour-permeable adhesive film Type of wound product is suitable for Dry non infected wounds, retention of lines, fixation of secondary dressings, protection of intact skin, protection of skin against friction, protection of newly epithelialized wounds Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change Up to 7 days Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Clinically infected wounds, bleeding or exuding wounds Rationale for inclusion in formulary Retention of lines, protection of intact skin, fixation of other dressings. Cost effective Waterproof |
| 13.11.06 | Hydrogen Peroxide Crystacide® | |
| 13.11.06 | Hydrogen Peroxide 3% Solution (10vols) | |
| 13.11.06 | Hydrogen Peroxide 6% Solution (20vols) | |
| 12.03.04 | Hydrogen Peroxide mouthwash BP | |
| 09.04 | Hydrolysed whey protein maltodextrin powder |
|
| 13.02.01 | Hydromol Cream® | Over the counter preparation suitable for self-care/purchase if appropriate |
| 13.02.01 | Hydromol ointment ® | Over the counter preparation suitable for self-care/purchase if appropriate |
| 13.02.01.01 | Hydromol® bath and shower | Over the counter preparation suitable for self-care/purchase if appropriate |
| 13.14.07 | Hydroquinone 5% w/w, hydrocortisone 1% w/w and tretinoin 0.1% w/w in a non-aqueous gel 0.3% w/v | |
| 13.02.01 | Hydrous ointment BP | Over the counter preparation suitable for self-care/purchase if appropriate |
| 09.01.02 | Hydroxocobalamin 1mg/ml injection | |
| 08.01.05 | Hydroxycarbamide | |
| 09.01.03 | Hydroxycarbamide | |
| 13.05.03 | Hydroxycarbamide | |
| 10.01.03 | Hydroxychloroquine | |
| 10.01.03 | Hydroxychloroquine | |
| 13.05.03 | Hydroxychloroquine | |
| 03.04.01 | Hydroxyzine | |
| 04.02.03 | Hyoscine | |
| 01.02 | Hyoscine Butylbromide Buscopan® | Tablet 10mg, Injection 20mg/ml |
| 04.06 | Hyoscine Hydrobromide | |
| 04.06 | Hyoscine Hydrobromide | £££ |
| 15.01.03 | Hyoscine Hydrobromide | For hyoscine patch, See chapter 4.6 |
| 03.07 | Hypertonic sodium chloride 7% Resp-Ease® | |
| 11.08.01 | Hypromellose 0.5% eye drops | |
| 06.06.02 | Ibandronic Acid 150mg | |
| 06.06.02 | Ibandronic Acid 50mg | |
| 06.06.02 | Ibandronic Acid injection | |
| 08.01.05 | Ibrutinib Imbruvica® |
|
| 07.01.01.01 | Ibuprofen Pedea® injection | |
| 10.01.01 | Ibuprofen | |
| 10.01.01 | Ibuprofen | |
| 10.03.02 | Ibuprofen gel | |
| 03.04.03 | Icatibant Firazyr® | Hospital Only- NHSE commissioned |
| 13.14.04 | Ichthammol 1% w/w and zinc oxide 15% w/w in YSP | |
| A5.08.09 | Ichthopaste | Zinc and Ichthammol bandage. Type of wound product is suitable for Venous leg ulcers Chronic eczema Dermatitis Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change Daily up to weekly dependant on skin and wound management. Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Do not use in any cases of sensitivity or allergy to ingredients Rationale for inclusion in formulary For treatment of dermatitis and chronic eczema when venous insufficiency is present. |
| 08.01.02 | Idarubicin Hydrochloride Capsules | |
| 08.01.05 | Idelalisib Zydelig® | |
| 02.05.01 | Iloprost nebules Vantavis® | NHS England commissioned |
| 08.01.05 | Imatinib Glivec® | in line with NICE |
| 05.01.02.02 | Imipenem with cilastatin Primaxin® | |
| 04.03.01 | Imipramine | |
| 13.08.01 | Imiquimod 3.75% Zyclara® | |
| 13.07 | Imiquimod 5% Aldara® | |
| 13.08.01 | Imiquimod 5% Aldara® | |
| 14.04 | Inactivated Influenza Vaccine (Split Virion) | |
| A5.03.02 | Inadine ® | Non-adherent dressing impregnated with povidone iodine (10%) Type of wound product is suitable for Mild local infection where there is low exudate levels, ischaemic wounds, dry, gangrenous digits with the aim to desiccate and auto-amputate. Dry-manage fixator sites Minor burns or skin trauma with local infection Duration dressing remains on wound before changing 1-3 days depending on uptake of iodine from dressing Frequency of dressing change 1-3 days depending on uptake of iodine from dressing Look at colour change of dressing (orange initially to white when all used) Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Iodine allergy or sensitivity Thyroid disorders Renal impairment Not suitable for children, pregnant or lactating women Rationale for inclusion in formulary Topical antimicrobial Non-adherent/pain free use No damage to granular or epithelial cells Easy application and removal Drying properties Efficacy against bacteria, fungi and viruses Cost effective. |
| 02.02.01 | Indapamide | Use 2.5mg tablets only |
| 13.10.05 | Indermil® | Hospital only |
| 20 | Indigo carmine |
|
| 06.04.01.01 | Indivina® tablets | |
| 07.01.01.01 | Indometacin Indocid PDA® | |
| 10.01.01 | Indometacin | |
| 10.01.01 | Indometacin | |
| 14.04 | Infanrix-IPV® | |
| 09.04 | Infatrini® |
|
| 09.04 | Infatrini® Peptisorb |
|
| 01.05.03 | Infliximab Remicade® | Infusion For specialist use only in line with NICE guidance below Commissioned in paediatrics by NHSE |
| 10.01.03 | Infliximab Remicade® | Hospital only |
| 13.05.03 | Infliximab | |
| 14.04 | Influenza vaccine | |
| 13.08.01 | Ingenol mebutate Picato® | |
| 08.02.03 | Inotuzumab ozogamicin Besponsa ® | In line with NICE Hospital only- NHSE commissioned |
| 09.09 | Instant Carobel® |
|
| 06.01.01.01 | Insulin Actrapid® | |
| 06.01.01.01 | Insulin Humulin® S | |
| 06.01.01.01 | Insulin Insuman® Rapid | |
| 06.01.01.01 | Insulin Aspart NovoRapid® | |
| 06.01.01.01 | Insulin Aspart Fiasp® |
|
| 06.01.01.02 | Insulin degludec 100 units/mL Tresiba® |
|
| 06.01.01.02 | Insulin degludec 100 units/mL Tresiba® |
|
| 06.01.01.02 | Insulin detemir Levemir® | |
| 06.01.01.02 | Insulin glargine 100 units/mL Lantus® | £ |
| 06.01.01.02 | Insulin glargine 100 units/mL biosimilar Abasaglar® |
|
| 06.01.01.02 | Insulin glargine 300 units/mL Toujeo® | Prescribe by brand |
| 06.01.01.02 | Insulin Glargine biosimilar Semglee® |
|
| 06.01.01.01 | Insulin Glulisine Apidra® | |
| 06.01.01.01 | Insulin Lispro 100 units/mL Humalog 100 units/mL ® | |
| 08.02.04 | Interferon Alfa | |
| 14.05 | INTERFERON GAMMA-1b | |
| 07.03.04 | Intra-uterine Contraceptive Devices Mini TT ®380 Slimline | |
| 07.03.04 | Intra-uterine Contraceptive Devices Nova-T® 380 | |
| 07.03.04 | Intra-uterine Contraceptive Devices T-Safe® CU 380 A QuickLoad | |
| 07.03.02.03 | Intra-uterine Progestogen Only System Mirena® | |
| 07.03.02.03 | Intra-uterine Progestogen Only System Jaydess® | |
| 06.02.02 | Iodine and Iodide |
|
| A5.03.02 | Iodoflex® | Cadexomer dressing containing iodine Type of wound product is suitable for Iodine paste in mesh form for chronic infected, sloughy wounds with moderate exudate eg pressure ulcers, leg ulcers, diabetic foot ulcers Can be used under compression bandaging MAX Duration dressing remains on wound before changing Up to 3 days Frequency of dressing change Daily for acute infection Up to 3 days for chronic wounds and infection, depending on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Allergy or sensitivity to iodine Precaution with large wounds due to absorption. Do not use more than 50g in a single application and no more than 150g in 7 days Dry necrotic wounds Thyroid disorders Renal impairment Not suitable for children, pregnant or lactating mothers Concurrent Lithium therapy Rationale for inclusion in formulary Anti microbial, broad spectrum, long acting/high absorption capacity Removes slough and debris to clean the wound bed Can be moulded to shape of the wound Alternative to honey products if allergy to bees |
| A5.03.02 | Iodosorb® | Cadexomer powder or ointment with iodine Type of wound product is suitable for Chronic exuding sloughy wounds eg leg ulcers, pressure ulcers, diabetic foot ulcers. Can be used under compression bandaging Duration dressing remains on wound before changing Up to 3 days Frequency of dressing change Daily for acute infection Up to 3 days for chronic infection Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Allergy to iodine products Dry necrotic tissue Not suitable for Children, pregnant or lactating mothers Thyroid disorders Renal impairment Needs at least twice weekly dressings for iodine to be effective Rationale for inclusion in formulary Antimicrobial, broad spectrum, long acting De-slough and cleans wound debris Non-adherant. Reduces trauma to wound and pain on dressing changes Easy application. Can fill cavities or awkward shaped wounds Alternative to honey based products if allergy to bees |
| 08.01.05 | Ipilimumab Yervoy® | |
| 03.01.02 | Ipratropium | |
| 02.05.05.02 | Irbesartan tablets | |
| 09.01.01.01 | Iron and Folic Acid Pregaday® | |
| 09.01.01.02 | Iron Isomaltoside Monofer® | Hospital only |
| 09.01.01.02 | Iron Sucrose Venofer® | Hospital use only |
| A5.12 | Irripod | Sterile sodium chloride solution Type of wound product is suitable for Wound cleansing, for topical irrigation of the eye Duration dressing remains on wound before changing As required Frequency of dressing change As required Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Single use External use only Rationale for inclusion in formulary Cost effective Cleansing of wounds |
| 09.04 | Isolecuine50® |
|
| 09.04 | Isoleucine 1000 |
|
| 05.01.09 | Isoniazid |
Isoniazid liquid 50mg in 5ml (unlicensed) |
| 06.01.01.02 | Isophane Insulin Insulatard® | |
| 06.01.01.02 | Isophane Insulin Humulin® I | |
| 06.01.01.02 | Isophane Insulin Insuman® Basal | |
| 02.07.01 | Isoprenaline | |
| 02.06.01 | Isosorbide Dinatrate | |
| 02.06.01 | Isosorbide Mononitrate | Tablets |
| 02.06.01 | Isosorbide Mononitrate MR | APC preferred brands:- |
| 13.06.02 | Isotretinoin | |
| 01.06.01 | Ispaghula Husk | Granules - Adequate fluid intake is important to prevent obstruction (6 – 8 cups per day) and should not to be taken immediately before bed - Unsuitable for frail patients who are likely to drink less than daily required volume of fluid - Fluid thickens on standing so should be taken as soon as possible as after mixing - Time to effect is approximately 48 – 72 hours |
| 05.02 | Itraconazole | |
| 05.02 | Itraconazole injection | |
| A5.02.02 | IV 3000 | Fixation dressing Type of wound product is suitable for For fixation of intravenous and subcutaneous catheter sites Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change Up to 7 days or when wet/soiled Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Sensitivity to any of the product components Not for use on pressure ulcers, burns or donor sites Strips and documentation label are not to be used as suture replacements or primary wound closure methods Rationale for inclusion in formulary Fixation of intravenous and subcutaneous devices |
| 09.04 | IVA Anamix® Infant |
|
| 02.06.03 | Ivabradine tablets | Supported by a RICaD, see link below. |
| 03.07 | Ivacaftor Kalydeco® | In line with NICE |
| 05.05.06 | Ivermectin | |
| 13.06.03 | Ivermectin 1% cream Soolantra® | |
| 13.05.03 | Ixekizumab Taltz® |
|
| A5.17 | Jelonet® | Paraffin gauze dressing Type of wound product is suitable for As a primary layer for use with Flamazine® or Flammercerium® Duration dressing remains on wound before changing 24 hours Frequency of dressing change Daily- occasionally alternate day Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Allergy to any ingredients. Rationale for inclusion in formulary Cost effective primary layer |
| 09.04.02 | Jevity® |
|
| 09.04.02 | Jevity®1.5 kcal |
|
| 09.04.02 | Jevity®Plus |
|
| 09.04.02 | Jevity®Plus HP |
|
| 09.04.02 | Jevity®Promote |
|
| 09.05.02.01 | Joulies Phosphate Solution |
|
| A5.08.04 | K- Lite | Lightweight knitted bandage Type of wound product is suitable for Designed for use on sprains/strains Can be used to prevent oedema, would require a wadding bandage to be applied beneath It is the second layer of a four layer compression bandage kit Where there is open skin, a primary dressing must be used Duration dressing remains on wound before changing Change in line with primary dressing Frequency of dressing change 1-7 days Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Known allergy to any components Not suitable for application of pressure on its own and therefore should be used with other bandage components for the treatment of venous ulcers Caution over bony prominences where the bandage can cause pressure Rationale for inclusion in formulary Cost effective Essential for providing support to a limb and as part of a bandage compression therapy kit |
| A5.08.07 | K Soft® | An absorbent non –woven, sub bandage wadding. Type of wound product is suitable for Provides padding , shaping and protection of the limb prior to the application of compression bandage therapy. Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change Daily up to weekly dependant on exudate and oedema management. Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Advised not to apply directly to skin as can cause irritation. Rationale for inclusion in formulary Essential for protecting a limb, padding and shaping Forms part of the compression bandage regime. Suitable for use with other formulary products. |
| A5.03.04 | Kendall AMD® | Absorbent, non adherent foam disc impregnated with PHMB. Double sided with a centre hole and radial slit Type of wound product is suitable for For use on pin sites, drains and tubes. Duration dressing remains on wound before changing 1-7 days Frequency of dressing change 1-7 days dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Not intended as a primary treatment for infection Do not use as a primary treatment for full thickness burns Not for patients sensitive to PHMB Rationale for inclusion in formulary Provides local exudate management and antimicrobial properties Absorbent Non adherent and semi occlusive For specialist use only |
| A5.17 | Kerlix ® | Gauze roll containing 0.2% Polyhexamethylene Biguanide (PHMB) Type of wound product is suitable for Colonised or infected wounds, with moderate to heavy exudate Duration dressing remains on wound before changing 3 days Frequency of dressing change 3 days Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Allergy to PHMB Do not use with Sodium hypochlorite ( Eusol) solutions, as this will deactivate PHM Do not apply gauze circumferentially as it has no stretch, and can become tight restricting circulation Rationale for inclusion in formulary Broad-spectrum antimicrobial agent that reduces bacterial colonization within the dressing and bacterial penetration through the dressing. Can be used in conjunction with Renasys Negative Pressure Therapy |
| 13.08.02 | Keromask® | |
| A5.01.02 | KerraMaxCare | Superabsorbent dressing Type of wound product is suitable for Highly exuding wounds as a primary or secondary dressing. Can be used under compression therapy Stackable as no backing present to hold exudate Duration dressing remains on wound before changing 1-7 days. Frequency of dressing change Dependent on level of exudate, usually daily or more frequently Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Do not cut or tear Rationale for inclusion in formulary Required for heavily exuding wounds. Hospital Use Only |
| A5.16 | Kerraped | A shoe to accommodate bandages and offload pressure from the front of the foot Type of wound product is suitable for Neuropathic foot ulcers or patients with bulky bandages who cannot wear their own footwear Duration product remains on wound before changing As required Frequency of use As required Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Ensure correct size is selected Rationale for inclusion in formulary Only footwear available for patients with neuropathic ulcers or bulky bandages |
| A5.16 | KerraPro® | Silicone pads designed to redistribute pressure from bony prominences. Type of wound product is suitable for Prevention and treatment of category (Stage/Grade) 1 pressure ulcers Duration dressing remains on wound before changing As required. Check skin daily. Frequency of dressing change As required, check skin daily. Pads will last up to 3 months Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Must only be used as part of a pressure ulcer prevention programme Not to be used on a grade 2, 3 4, unstageable or deep tissue injury pressure ulcer unless directed by a clinical specialist Known sensitivity to silicone Do not use as a wound dressing Do not apply directly onto broken skin If skin macerates beneath, ensure the area is being checked and washed daily and consider utilising a cotton stockinette to reduce humidity Rationale for inclusion in formulary Cost effective Available in a large range of shapes and sizes Accessible pressure ulcer prevention medical device Reusable on the same patient for up to 3 months by washing with soap and water and thoroughly drying |
| 09.04 | KetoCal® 3:1 |
|
| 09.04 | KetoCal® 4.1 |
|
| 09.04 | KetoCal® 4:1 LQ |
|
| 13.10.02 | Ketoconazole 2% | ££ |
| 13.09 | Ketoconazole 2% shampoo | Over the counter preparation suitable for self-care/purchase if appropriate |
| 11.08.02 | Ketorolac Acular® | |
| 09.04 | KeyOmega® |
|
| 09.04 | Kindergen® |
|
| A5.02.03 | kliniderm Foam Silicone | Polyurethane foam with adhesive silicone wound contact layer Type of wound product is suitable for Suitable for acute and chronic wounds including leg ulcers, pressure ulcers, superficial and partial thickness burns, donor sites, post operative wounds and skin abrasions. Suitable for low to moderately exuding wounds for patients with fragile skin Available in border and non border Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change 1-7 days – dependant on exudate level Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Known product or component sensitivity eg Silicone Rationale for inclusion in formulary Wound contact surface is coated with a layer of soft silicone which reduces trauma to delicate tissue. Range of shapes and sizes available. |
| 06.04.01.01 | Kliofem® tablets | |
| 06.04.01.01 | Kliovance® |
|
| A5.08.02 | Knit -band® | Cellulose contour bandage used for retention of non adhesive dressing products Type of wound product is suitable for Retention bandage Duration dressing remains on wound before changing Change in line with dressing change Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Take care to apply joint below to joint above. Always use a primary dressing Rationale for inclusion in formulary Most cost effective choice. |
| A5.08.06 | Ko-Flex® | A water resistant vapour permeable cohesive bandage Type of wound product is suitable for Venous ulceration, oedema, Managing sprains and strains and following orthopaedic surgery Forms part of the K four bandage system Duration dressing remains on wound before changing 1 to 7 days Frequency of dressing change Dependant on exudate levels if wound present or oedema management . Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Not recommended on those patients with an ABPI lower than 0.8. Contains latex Rationale for inclusion in formulary Cohesive bandage that can be used alongside other formulary products Forms the 4th layer of a four layer compression bandage system |
| A5.03.04 | Kytocel® | Absorbent gelling fibre wound dressing Type of wound product is suitable for Moderate to heavily exuding chronic and acute wounds that are sloughy and clinically infected. Haemostatic properties for minor bleeds in superficial wounds Autolytic debridement properties Duration dressing remains on wound before changing 1-3 days Frequency of dressing change 1-3 days, dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Allergy to Shellfish (Chitin) Full thickness burns Heavily bleeding wounds Dry wounds Rationale for inclusion in formulary Cost effective Alternative to available antimicrobials Can be used on heavily exuding wounds |
| 02.04 | Labetalol injection | |
| 02.04 | Labetalol tablets |  Specific indication- Pregnancy |
| 04.08.01 | Lacosamide | |
| 01.06.04 | Lactulose | Solution |
| 05.03.01 | Lamivudine Epivir® | |
| 05.03.01 | Lamivudine Zeffix® | |
| 04.02.03 | Lamotrigine | |
| 04.08.01 | Lamotrigine | MHRA Advice Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history. |
| 08.03.04.03 | Lanreotide Somatuline® LA | Palliative Care use only Oncology Acromegaly |
| 08.03.04.03 | Lanreotide Somatuline Autogel® | Palliative Care use only Oncology Acromegaly |
| 01.03.05 | Lansoprazole | Capsules 15mg, 30mg - Capsules are more cost effective than tablets - Can be opened and beads swallowed without crushing, or can be mixed with food or drink |
| 01.03.05 | Lansoprazole dispersible | Orodispersible tablets 15mg, 30mg Orodispersible tablets cost twice as much as capsules Restricted Second choice - for use in patients with swallowing difficulties or who are on enteral tube feeding. Also licensed to be given via a NG tube or oral syringe if diluted in 5-10 ml water |
| 09.05.02.02 | Lanthanum |
|
| 08.01.05 | Lapatinib Tyverb® | |
| A5.10 | LarvE | Free range: Biomonde Larvae 100/200 or BioBag Biosurgical treatment for the debridement and cleansing of wounds consisting of aseptically produced living larvae. The BioBag is presented in the five (5) configurations listed below. The larvae are Lucilia sericata contained in a sterile polyester net bag with a sterile PVA spacer cube, presented in a sterile transport container. BioBag 50 at least 50 larvae 25 x 40mm 1 8x8x10 BioBag 100 at least 100 larvae 50 x 40mm 1 12x12x10 BioBag 200 at least 200 larvae 60 x 50mm 1 25x10x10 BioBag 300 at least 300 larvae 120 x 60mm 2 25x10x10 BioBag 400 at least 400 larvae 100 x 100mm 2 25x10x10 Free range larvae, larvae and 30 x 30 flat retention net plus kit pack, larvae and 40 x 60cm boot retention net plus kit pack. Additional 100 or 200 larvae available. Type of wound product is suitable for The BioMonde Larval Debridement Therapy Products are indicated for debridement of non-healing necrotic skin and soft tissue wounds, including pressure ulcers, venous stasis ulcers, neuropathic foot ulcers, and non-healing traumatic or post-surgical wounds. Duration dressing remains on wound before changing and frequency of dressing change An application of BioBag can be left in place for up to 4 days, dependent on the condition of the wound. If the wound is not sufficiently debrided after 4 days, the treatment can be repeated with a fresh application of BioBag. The treatment should be stopped as soon as the wound is sufficiently debrided or if no improvement is observed after 3 or more applications. The total number of treatment cycles will depend on the characteristics of the wound, the response of the patient to LDT and the aim of the therapy. Most ulcers are completely debrided within 1 to 6 treatment cycles. If exudate production is excessive, the secondary dressing may be changed as required while leaving the BioBag undisturbed. Frequent removal of the outer dressing will also help to control the odour associated with the liquefied necrotic tissue Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Larvae should not be used in patients with known hypersensitivities to fly larvae, polyester, PVA (polyvinyl alcohol) or the components of the media on which the larvae are raised (including soya protein, yeast protein, potato starch and bovine protein) as this may result in dermatitis or more severe immunological reactions in susceptible individuals. If treatment is undertaken then these patients should be under strict medical supervision for the duration of the treatment with immediate access to care. Patients with life or limb-threatening, rapidly advancing infections should not be treated with as LDT may interfere with the close and frequent observation that these patients require. Should not be used as first line therapy of infected tendon and bone. These wounds should be treated surgically and/or with antibiotics before using LDT. Should not be used to treat wounds which are not directly exposed to the outside. Wounds should never be allowed to close over the larvae either intentionally or unintentionally. Should not be used on wounds with an inadequate blood supply as this ultimately reduces the ability of the wound to heal. LDT will enlarge the wound as necrotic tissue is debrided but the resulting clean wound is at risk from re-infection. Although some mild bleeding is common during LDT, larvae should not be used on wounds that have a tendency to bleed or wounds close to an exposed major blood vessel, especially if considered to be necrotic as this can lead to rupture of the blood vessels which could be life-threatening. If LDT is attempted, the patient must remain under strict medical supervision for the duration of the treatment. Should not be used on patients with an inborn or medication-induced coagulopathy or in patients being treated with anticoagulants. If these patients are treated with LDT, they should remain under strict medical supervision for the duration of the treatment. Should never be used in sterile body cavities. Should be used with caution on wounds over adjacent exposed organs or leading to a body cavity, and only under close medical supervision for the duration of the treatment. Data are not available concerning the antibiotic / antiseptic activity of maggots and therefore any infected wound should receive standard antibiotic care. Rationale for inclusion in formulary Only available larval therapy on prescription. Rapid debridement of chronic wounds Can be utilised in the community |
| 11.06 | Latanoprost 0.005% with Timolol 0.5% | |
| 11.06 | Latanoprost eye drops | |
| 11.06 | Latanoprost PF Eye Drops Monopost | |
| 05.03.03.02 | Ledipasvir- sofosbuvir Harvoni® | In line with NICE |
| 10.01.03 | Leflunomide | Supported by ESCA, see link below. |
| 08.02.04 | Lenalidomide | |
| 09.01.06 | Lenograstim | |
| 08.01.05 | Lenvatinib Kisplyx ® | In line with NICE |
| 08.03.04.01 | Letrozole | |
| 06.07.02 | Leuprorelin | |
| 08.03.04.02 | Leuprorelin Acetate Prostap® SR | |
| 08.03.04.02 | Leuprorelin Acetate Prostap® 3 | |
| 05.05.02 | Levamisole | |
| 04.08.01 | Levetiracetam Desitrend® | MHRA Advice It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors |
| 04.08.01 | Levetiracetam | MHRA Advice It is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific reasons such as patient anxiety and risk of confusion or dosing errors |
| 05.01.12 | Levofloxacin tablets | |
| 05.01.12 | Levofloxacin infusion | |
| 11.03.01 | Levofloxacin Oftaquix | |
| 04.06 | Levomepromazine | |
| 04.02.01 | Levomepromazine injection | |
| 04.02.01 | Levomepromazine tablets | |
| 07.03.05 | Levonogrestrel Levonelle® 1500 | |
| 07.03.02.01 | Levonorgestrel 30mcg Norgeston® | |
| 06.02.01 | Levothyroxine | |
| 15.02 | Lidocaine laryngojet® | |
| 12.03.01 | Lidocaine 10% mouth spray | |
| 15.02 | Lidocaine 2.5% with Prilocaine 2.5% EMLA® | |
| 15.02 | Lidocaine 4% cream LMX® | |
| 15.02 | Lidocaine 5% ointment | |
| 04.07.03 | Lidocaine 5% patch Versatis® | Approved only in patients who have been treated in line with NICE CG173 Neuropathic pain in adults: pharmacological management in non-specialist settings but are still experiencing neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia)
|
| 02.03.02 | Lidocaine hydrochloride | |
| 15.02 | Lidocaine injection | |
| 15.02 | Lidocaine with Adrenaline Lignospan® | |
| 15.02 | Lidocaine with Adrenaline Xylocaine® | |
| 15.02 | Lidocaine2% with Chlorhexidine 0.25% Instillagel® | |
| A5.11 | LimbO Waterproof protector | Waterproof protector, non slip latex free with a flexible seal at the opening Type of wound product is suitable for Used to keep arm, PICC, leg and foot dressings dry, can be fully submerged in water Rationale for inclusion in formulary Multiple sizing for legs and arms |
| 01.06.07 | Linaclotide Constella▼® |
|
| 06.01.02.03 | Linagliptin Trajenta® | In line with NICE |
| 05.01.07 | Linezolid oral formulations | |
| 05.01.07 | Linezolid infusion | |
| 06.02.01 | Liothyronine | |
| 20 | Lipiodol |
|
| 09.04 | Lipistart® |
|
| 13.02.01 | Liquid and White Soft Paraffin Ointment (50:50) | Over the counter preparation suitable for self-care/purchase if appropriate |
| A5.13 | Liquid paraffin / white soft paraffin 50:50 | Emollient ointment containing liquid paraffin and white soft paraffin To assist the skin in retaining moisture Type of wound product is suitable for For use on all dry skin conditions including eczema and psoriasis Frequency of use Daily or more frequently if required Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Allergy or hypersensitivity to any of the ingredients Rationale for inclusion in formulary Treatment of dry skin conditions. Dermatology approved |
| 09.04 | Liquigen® |
|
| 06.01.02.03 | Liraglutide Victoza® | |
| 04.04 | Lisdexamfetamine Elvanse® | Please note that commissioning discussion is underway. However the present status is as follows:- |
| 02.05.05.01 | Lisinopril tablets | |
| 04.02.03 | Lithium Carbonate M/R tablets Priadel® | |
| 04.02.03 | Lithium Citrate liquid | |
| A5.03.01 | L-Mesitran ® | A hydro active gel dressing containing medical grade honey available without or with an adhesive film border. L- Mesitran has anti bacterial properties and can debride and reduce malodour. Type of wound product is suitable for Burns, chronic wounds, necrotic/sloughy wounds, surgical wounds, diabetic ulcers with caution, donor sites, fungating wounds. Max Duration dressing remains on wound before changing 3-7 days Frequency of dressing change 3- 7 days, dependent on exudate level Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Known sensitivity to dressing and any of its components use with caution in patients with bee venom allergy Not suitable for full thickness burns/deep narrow cavities Caution must be exercised when applying to diabetic patients. Blood glucose levels must be monitored. Rationale for inclusion in formulary Desloughing, Antimicrobial, Deodorising |
| 09.04 | Locasol ® |
|
| 04.03.01 | Lofepramine | |
| 04.10.03 | Lofexidine BritLofex® | |
| 08.01.01 | Lomustine capsules | |
| 01.04.02 | Loperamide |
|
| 09.04 | Lophlex® |
|
| 05.03.01 | Lopinavir and Ritonavir Kaletra® | |
| 09.04 | Loprofin SnoPro |
|
| 09.04 | Loprofin® PKU Drink |
|
| 09.04 | Loprofin® Sno-Pro |
|
| 03.04.01 | Loratadine | OTC preparation suitable for self-care/purchase if appropriate |
| 04.01.02 | Lorazepam | |
| 04.01.02 | Lorazepam | Oct 2018: supply issues with injection |
| 09.04 | Lorenzo’s oil |
|
| 02.05.05.02 | Losartan tablets | |
| 11.04.01 | Loteprednol Etabonate 0.5% Lotemax® | |
| 09.04 | Low fat 1+ module |
|
| 03.01.05 | Low range peak flow meter | |
| 06.04.01.01 | Lubion® Injection |
|
| 03.15 | Lumacaftor-ivacaftor Orkambi® | In line with NICE |
| 08.03.04.03 | Lutetium (177Lu) oxodotreotide | In line with NICE Hospital only - NHSE commissioned |
| 05.01.03 | Lymecycline | |
| 13.06.02 | Lymecycline | Please refer to Antimicrobial guidelines |
| A5.09.02 | Lymphoedema garments | Based on assessment |
| 01.06.04 | Macrogol Laxido® | Oral powder Prescribe as Laxido |
| 01.06.05 | Macrogols Klean-Prep® | Oral powder |
| 01.06.05 | Macrogols Moviprep® | Oral powder sachet |
| 09.05.01.03 | Magnaspartate ® sachets | |
| 09.05.01.03 | Magnesium citrate tablets | |
| 09.05.01.03 | Magnesium Glycerophosphate oral | |
| 09.05.01.03 | Magnesium Sulphate | |
| 13.10.05 | Magnesium Sulphate Paste BP | Over the counter preparation suitable for self-care/purchase if appropriate |
| 01.01.01 | Magnesium Trisilicate Mixture BP | Suspension High sodium content Use with caution in renal impairment |
| A5.11 | Magnide | Application aid for closed toe stockings/ compression garments |
| 13.10.04 | Malathion | Over the counter preparation suitable for self-care/purchase if appropriate |
| 02.02.05 | Mannitol infusion | |
| 03.07 | Mannitol inhalation Bronchitol ® | Hospital only |
| 05.03.01 | Maraviroc | |
| 09.04 | Maxijul® Super Soluble |
|
| 09.04 | MCT Procal® |
|
| 14.04 | Measles, Mumps and Rubella Vaccine, Live (MMR) | |
| 05.05.01 | Mebendazole | |
| 01.02 | Mebeverine Hydrochloride | Tablet 135mg Prescribe standard release tablets only; modified release (MR) preparations are non-formulary |
| 06.07.04 | Mecasermin Increlex® | |
| A5.15 | MediHoney barrier cream | Barrier cream containing active Medihoney. Helps to reduce inflammation Type of wound product is suitable for Treatment of incontinence related lesions Treats blistered skin Prevention and treatment of maceration and excoriation Treats candidiasis and intertrigo Frequency of use At each episode of hygiene Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Patch test before use Rationale for inclusion in formulary Suitable for neonates and children Treats fungal infections as well as incontinence associated lesions Reduces inflammation Can be applied to broken skin |
| 09.04 | Medium-chain Triglyceride (MCT) Oil |
|
| 06.04.01.02 | Medroxyprogesterone Acetate | |
| 07.03.02.02 | Medroxyprogesterone Acetate Depo-Provera® | |
| 07.03.02.02 | Medroxyprogesterone acetate Sayana Press® | |
| 08.03.02 | Medroxyprogesterone Acetate | |
| 10.01.01 | Mefenamic Acid | |
| A5.07.03 | Mefix | Permeable, aperture non woven, synthetic adhesive tape For securing dressings. Frequency of dressing change Determined by wound type and dressing change Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) None listed Rationale for inclusion in formulary Available on drug tariff. Different availability of sizes in comparison to Clinipore for difficult to dress areas. Some stretch and flexibility to improve conformity and adhesion. Can be used to secure dressings rather than bandages. |
| 05.04.01 | Mefloquine Lariam® | |
| 08.03.02 | Megestrol Acetate | |
| 04.01.01 | Melatonin Circadin ® | |
| 04.01.01 | Melatonin | |
| 08.01.01 | Melphalan Tablets | |
| 04.11 | Memantine | The APC's view is that on clinical grounds, the status of these drugs for dementia should be amber, with a framework in place in primary care before transfer. HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED. |
| 09.06.06 | Menadiol Sodium Phosphate | |
| 14.04 | Meningococcal A, C, W135, and Y conjugate vaccine | |
| 14.04 | Meningococcal group B Vaccine Bexsero® | |
| 14.04 | Meningococcal group C conjugate vaccine | |
| 13.03 | Menthol in Aqueous cream |
Over the counter preparation suitable for self-care/purchase if appropriate |
| 05.04.04 | Mepacrine Hydrochloride | |
| 13.15 | Mepacrine Hydrochloride | |
| A5.04.02 | Mepiform | Silicone sheet for scar treatment Type of wound product is suitable for Not for use on open wounds- to be applied on healed scar only. This is not a dressing but a scar treatment Duration dressing remains on wound before changing 23 hours Frequency of dressing change Daily Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Do not use on open or infected wounds. Do not use on skin affected by acne. Discontinue use if a rash or itching occur. Rationale for inclusion in formulary Scar therapy Silicone sheets have been shown to soften, flatten scarring aiding movement, nerve sensations and function. Cost effective. |
| A5.02.03 | Mepitel | Soft polymer non-adherent dressing without pad Type of wound product is suitable for Primary wound contact layer, non adherent, traumatic and chronic wounds Requires secondary dressing Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change Up to 7 days Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Heavily bleeding wounds Any sensitivity to silicone Rationale for inclusion in formulary Non-adherent primary wound contact layer to protect skin tears, fragile skin, primary contact layer for use under topical negative pressure |
| 03.14 | Mepolizumab (Nucala®) | In line with NHSE |
| A5.01.02 | Mepore | Type of wound product is suitable for Post operative closed surgical wounds or simple wounds with up to light amounts of exudate. Can be used as a protective dressing for sutured post operative wounds. Can be used as a protective dressing for newly epithelialized wounds. Can be used for small traumatic wounds. Duration dressing remains on wound before changing Up to 7 days Frequency of dressing change 1-7 days. If daily change is required - review product choice Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Known product or component sensitivity Rationale for inclusion in formulary Sutured surgical wounds for protection. Can be used as a protective dressing for newly epithelialized wounds. Can be used for small traumatic wounds. |
| 04.07.02 | Meptazinol Meptid® | |
| 01.05.03 | Mercaptopurine | Tablet 50mg Maintenance of remission of acute ulcerative colitis and Crohn’s disease in adults – unlicensed but in line with national guidelines For use in Inflammatory Bowel Disease (IBD) as per effective shared care agreement (ESCA). See link below. |
| 08.01.03 | Mercaptopurine Tablets | |
| 09.04 | Meritene energis |
|
| 03.13 | Meropenem | Hospital only |
| 05.01.02.02 | Meropenem | |
| 01.05.01 | Mesalazine Mezavant® XL | ££££££ |
| 01.05.01 | Mesalazine tablets, MR tablets, granules, suppositories, enemas | Octasa is preferred brand of choice UHB and HeFT. Other brands – Pentasa, Asacol, Asacol MR, Salofalk (granules/enema), Mezavant XL. |
| 01.05.01 | Mesalazine Salofalk® | Granules and enemas |
| 01.05.01 | Mesalazine Octasa® | ££££££ |
| 07.03.01 | Mestranol 50mcg/norethisterone 1mg Norinyl-1® | |
| A5.15 | Metanium ointment | Barrier preparation Type of wound product is suitable for For relief of the symptoms of nappy rash Frequency of use Spread the ointment thinly so the skin texture can be clearly seen through it. Repeat at each nappy change. Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Not to be used on adults in conjunction with containment products for incontinence due to the inclusion of light liquid and white paraffin in the ingredients, which will repel urine/faeces back onto the skin. Any allergy to the listed ingredients Overdose is unlikely when Metanium Nappy Rash Ointment is used as instructed for treating nappy rash. However, as this product contains titanium salicylate, accidental ingestion or excessive topical application could lead to symptoms of salicylate poisoning. Rationale for inclusion in formulary Dermatology approved |
| 13.02.02 | Metanium® |
Over the counter preparation suitable for self-care/purchase if appropriate |
| 02.07.02 | Metaraminol | |
| 06.01.02.02 | Metformin | |
| 06.01.02.02 | Metformin M/R | |
| 06.01.02.02 | Metformin oral solution SF | |
| 04.07.02 | Methadone | For use in opioid dependence, see section 4.10.3 |
| 03.09.01 | Methadone Hydrochloride Methadone® Linctus | Palliative care only |
| 04.10.03 | Methadone injection | |
| 04.10.03 | Methadone oral solution | |
| 04.10.03 | Methadone tablets | |
| 05.01.13 | Methenamine Hippurate | |
| 01.05.03 | Methotrexate | Cytotoxic- do not crush and disperse in water For use in active Crohn's disease (unlicensed indication supported by APC) as per effective shared care agreement (ESCA). See link below. |
| 04.13 | Methotrexate | Specialist use only for neurological conditions |
| 13.05.03 | Methotrexate | |
| 08.01.03 | Methotrexate 2.5mg Tablets | |
| 10.01.03 | Methotrexate 2.5mg tablets | Supported by ESCA, see link below. Should only be prescribed as 2.5mg tablets (Local agreement following National Patient Safety Agency alert) |
| 03.12 | Methotrexate tablets |
|
| 09.01.03 | Methoxy Polyethylene Glycol-Epoetin Beta Mircera® | |
| 13.05.02 | Methoxypsoralen | |
| 13.08.01 | Methyl-5-Aminolevulinate Metvix® | |
| 02.05.02 | Methyldopa tablets | |
| 04.04 | Methylphenidate Modified-Release | Please note that commissioning discussion is underway. However the present status is as follows:- Birmingham CrossCity CCG, Birmingham South Central CCG, Sandwell & West Birmingham CCG Supported with an ESCA- Solihull CCG |
| 04.04 | Methylphenidate tablets | Please note that commissioning discussion is underway. However the present status is as follows:- Birmingham CrossCity CCG, Birmingham South Central CCG, Sandwell & West Birmingham CCG Supported with an ESCA- Solihull CCG |
| 10.01.02.02 | Methylprednisolone Acetate Depo-Medrone® | |
| 06.03.02 | Methylprednisolone acetate injection Depo-Medrone® | |
| 10.01.02.02 | Methylprednisolone Acetate/ Lidocaine Depo-Medrone® with Lidocaine | |
| 06.03.02 | Methylprednisolone sodium succinate injection Solu-Medrone ® | |
| 06.03.02 | Methylprednisolone tablets | In line with NICE |
| 02.05.01 | Metirosine | |
| 01.02 | Metoclopramide | Not recommended for patients aged 20 years and below due to risk of dystonic reactions See MHRA guidance below for restrictions on use in younger patients |
| 04.06 | Metoclopramide | |
| 04.06 | Metoclopramide injection | in palliative care
|
| 10.01.03 | Metoject® | Metoject is APC preferred brand in view of additional patient safety characteristics. Supported by ESCA, see link below. Check cytotoxic disposal arrangements locally |
| 02.02.01 | Metolazone | Specialist recommendation (unlicensed) Use with local trust approval. Available from "special-order" manufacturers or specialist-importing companies. |
| 02.04 | Metoprolol tartrate | |
| 02.04 | Metoprolol tartrate injection | |
| 05.01.11 | Metronidazole Suppositories | |
| 05.01.11 | Metronidazole | |
| 05.01.11 | Metronidazole infusion | |
| 07.02.02 | Metronidazole Zidoval® | |
| 13.10.01.02 | Metronidazole 0.75% Anabact® | |
| 13.10.01.02 | Metronidazole 0.75% Rozex® | |
| 13.10.01.02 | Metronidazole 0.75% Acea® | |
| A5.16 | metronidazole 0.75% gel Anabact® | Type of wound product is suitable for Malodourous fungating wounds. Requires a secondary dressing Duration preparation remains on wound before changing Apply 1-2 times daily following cleansing Frequency of use 1-2 times daily for a maximum of 8 weeks. Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Avoid exposure to strong sunlight or UV light Not to be used on a patient with known sensitivity to any components Avoid contact with eyes Not for use of any other aetiology of wound as odour control. Rationale for inclusion in formulary Odour control for fungating tumours |
| 06.07.03 | Metyrapone Metopirone® | |
| 02.03.02 | Mexiletine hydrochloride | unlicensed Use with local trust approval. Available from "special-order" manufacturers or specialist importing companies. |
| 05.02.04 | Micafungin | |
| 07.02.02 | Miconazole Gyno-Daktarin® |
|
| 11.03.02 | Miconazole 1% eye drops | |
| 13.10.02 | Miconazole 2% | |
| 12.03.02 | Miconazole oral gel | |
| 04.08.02 | Midazolam buccal liquid Buccolam® | |
| 02.07.02 | Midodrine Bramox® | |
| 08.01.05 | Midostaurin Rydapt® | In line with NICE NHSE commissioned |
| 08.02.04 | Mifamurtide | |
| 07.01.02 | Mifepristone Mifegyne® | |
| 05.01.03 | Minocycline | |
| 07.04.02 | Mirabegron Betmiga® | |
| 04.03.04 | Mirtazapine | |
| 01.03.04 | Misoprostol Cytotec® | Tablet 200mg For specialist initiation only |
| 07.01.01 | Misoprostol | |
| 11.99.99.99 | Mitomycin C | |
| 08.01.05 | Mitotane Lysodren® | |
| 09.04 | MMA/PA amp 5 |
|
| 09.04 | MMA/PA Anamix® Infant |
|
| 04.03.02 | Moclobemide tablets | |
| 04.04 | Modafinil |
|
| 09.04 | Modjul® Flavour System |
|
| 09.04 | Modulen IBD® |
|
| 13.04 | Mometasone Furoate 0.1% | Potency: potent |
| 12.02.01 | Mometasone Furoate nasal spray | |
| 09.04 | Monogen® |
|
| 03.03.02 | Montelukast | |
| 04.07.02 | Morphine | |
| 04.07.02 | Morphine | |
| 05.01.12 | Moxifloxacin | |
| 02.05.02 | Moxonidine tablets | |
| 09.04 | MSUD Amino 5 |
|
| 09.04 | MSUD Anamix® Infant |
|
| 09.04 | MSUD Anamix® Junior |
|
| 09.04 | MSUD Anamix® Junior LQ |
|
| 09.04 | MSUD cooler® 10 |
|
| 09.04 | MSUD cooler® 15 |
|
| 09.04 | MSUD cooler® 20 |
|
| 09.04 | MSUD express® 15 |
|
| 09.04 | MSUD express® 20 |
|
| 09.04 | MSUD Gel® |
|
| 09.04 | MSUD Lophlex® LQ 20 |
|
| 09.06.07 | Multivitamin preparations Abidec® | |
| 09.06.07 | Multivitamin preparations Dalivit® | |
| 09.06.07 | Multivitamin Supplement Paravit-CF® | Capsule, liquid.
|
| 13.10.01.01 | Mupirocin 2% | Please refer to Primary care antimicrobial guidelines |
| 12.02.03 | Mupirocin 2% in White Soft Paraffin Bactroban Nasal® | |
| 09.06.07 | Mutivitamins | |
| 04.13 | Mycophenolate | Specialist use only for neurological conditions |
| 13.05.03 | Mycophenolate | |
| 08.02.01 | Mycophenolate Mofetil | Post transplant- new patients Post transplant-patients initiated pre April 2013 |
| 10.02.01 | Mycophenolate mofetil | |
| 20 | N acetyl cysteine |
|
| A5.01.01 | N/A Ultra | Type of wound product is suitable for For flat granulating and epithelising wound for non to heavy exudate levels where adherence may occur. To be used as a primary dressing with a secondary for absorption. Duration dressing remains on wound before changing 7 days maximum Frequency of dressing change 1-7 days, depending on levels of exudate Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Known product or component sensitivity eg silicone Use with care if wound is bleeding heavily Rationale for inclusion in formulary To be used to reduce adherence to wound bed |
| 03.07 | N-Acetylcysteine nebulised | Hospital only |
| 02.06.04 | Naftidrofuryl Oxalate capsules | |
| 04.10.01 | Nalmefene | Restricted to Specialist Substance Misuse Services only The Nalmefene for reducing alcohol consumption technology appraisal (TA325) recommends this drug as a possible treatment for people with alcohol dependence who: • are still drinking more than 7.5 units per day (for men) and more than 5 units per day (for women) 2 weeks after an initial assessment and • do not have physical withdrawal symptoms and • do not need to either stop drinking straight away or stop drinking completely The guidance also recommends that nalmefene should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption. |
| 01.06.06 | Naloxegol |
|
| 04.10.03 | Naloxone | |
| 04.10.01 | Naltrexone | |
| 04.10.03 | Naltrexone Nalorex® | |
| 06.04.03 | Nandrolone Deca-Durabolin® | |
| 10.01.01 | Naproxen | |
| 08.02.04 | Natalizumab Tysabri® | |
| 09.04 | Neocate® Junior |
|
| 09.04 | Neocate® LCP |
|
| 09.04 | Neocate® Syneo |
|
| 11.04.02 | Neodocromil 2% eye drps Rapitil® | |
| 05.01.04 | Neomycin Sulphate | |
| 10.02.01 | Neostigmine injection | Hospital only |
| 10.02.01 | Neostigmine tablets | |
| 09.04 | Nepro® |
|
| 05.03.01 | Nevirapine | |
| 02.06.03 | Nicorandil tablets | Specialist initiation |
| 09.06.02 | Nicotinamide | |
| 13.06.01 | Nicotinamide 4% gel | |
| 04.10.02 | Nicotine replacement therapy | |
| 02.06.02 | Nifedipine | Standard release capsules and Modified Release preparations: Brand rationalisation- APC preferred brands:- |
| 07.01.03 | Nifedipine | |
| 08.01.05 | Nilotinib Tasigna® | In line with NICE |
| 02.06.02 | Nimodipine Nimotop® | |
| 03.11 | Nintedanib Ofev®
| |
| 08.01.05 | Nintedanib Vargatef® | |
| 08.01.05 | Niraparib | |
| 08.01.05 | Niraparib | |
| 05.01.07 | Nitazoxanide | Hospital use only |
| 05.01.13 | Nitrofurantoin | |
| 08.02.03 | Nivolumab Opdivo® | In line with NICE Hospital only- NHSE Commissioned |
| 02.07.02 | Noradrenaline / Norepinephrine | |
| 06.04.01.02 | Norethisterone |
|
| 07.03.02.01 | Norethisterone Noriday® | |
| 08.03.02 | Norethisterone | |
| 05.01.12 | Norfloxacin | |
| 14.05 | Normal immunoglobulin Subgam® | |
| 14.05 | Normal immunoglobulin Vivaglobin® | |
| 14.05.01 | Normal immunoglobulin for Intramuscular use | |
| 14.05.01 | Normal immunoglobulin for Subcutaneous use | |
| 06.04.01.01 | Novofem® tablets | |
| 09.09 | Nutilis® Clear |
|
| 09.04 | Nutilis® Complete Stage 1 |
|
| 09.04 | Nutramigen® 1 with LGG |
|
| 09.04 | Nutramigen® 2 with LGG |
|
| 09.04 | Nutramigen® Puramino |
|
| 09.04 | Nutricrem® |
|
| 09.04 | Nutrini® |
|
| 09.04 | Nutrini® Energy |
|
| 09.04 | Nutrini® Energy Multi Fibre |
|
| 09.04.02 | Nutrini® Low Energy Multi Fibre | Child under 12 years
|
| 09.04 | Nutrini® Multi Fibre |
|
| 09.04 | Nutrini® Peptisorb |
|
| 09.04 | Nutrini® Peptisorb Energy |
|
| 09.04.02 | Nutriprem® 1 | Child under 12 years
|
| 09.04.02 | Nutriprem® 2 | Child under 12 years
|
| 09.04.02 | Nutriprem® 2 | Child under 12 years
|
| 09.04.02 | Nutrison Peptisorb® |
|
| 09.04.02 | Nutrison® | First line
|
| 09.04.02 | Nutrison® Soya |
|
| 09.04.02 | Nutrison® Soya Multi Fibre |
|
| 09.04.02 | Nutrison®1000 Complete Multi Fibre |
|
| 09.04.02 | Nutrison®1200 Complete Multi Fibre |
|
| 09.04.02 | Nutrison®800 Complete Multi Fibre |
|
| 09.04.02 | Nutrison®Concentrated |
|
| 09.04.02 | Nutrison®Energy |
|
| 09.04.02 | Nutrison®Energy Multi Fibre |
|
| 09.04.02 | Nutrison®MCT |
|
| 09.04.02 | Nutrison®Multi Fibre | First line
|
| 09.04.02 | Nutrison®Protein Plus |
|
| 09.04.02 | Nutrison®Protein Plus Multi Fibre |
|
| 05.02 | Nystatin oral suspension | |
| 12.03.02 | Nystatin 100,000units/ml suspension | |
| A5.05.02 | Oakmed Option Wound Manager | Wound drainage system consisting of a hydrocolloid adhesive wafer and a drainable drainage bag Type of wound product is suitable for Complex abdominal wounds, moderate to large fistula’s, orthopaedic wounds or fungating wounds with high levels of exudate, that are unmanaged with conventional dressings. Max Duration dressing remains on wound before changing Empty drainage bag as required. If no port for drainage, change as required. Frequency of dressing change As long as adhesive remains intact whilst being mindful of skin integrity Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Known product component sensitivity to hydrocolloid (Gelatine and Pectin) Low to moderate exuding wounds Do not use if a conventional dressing can manage the exudate levels Rationale for inclusion in formulary Various size selection with drainage ports and windows For highly exuding wounds that conventional dressings cannot manage the exudate levels |
| 01.09.01 | Obeticholic acid Ocaliva® | |
| 08.02.03 | Obinutuzumab Gazyvaro® | In line with NICE Hospital only- NHS England commissioned |
| 08.02.03 | Ocrelizumab | In line with NICE |
| 11.08.02 | Ocriplasmin Jetrea® | |
| 12.02.03 | Octenidine hydrochloride Octenisan® md Nasal gel | |
| 13.01 | Octenisan® | |
| 13.11.02 | Octenisan® antimicrobial wash lotion | |
| 01.09 | Octreotide | Injection For specialist gastroenterologist initiation for intestinal secretions |
| 08.03.04.03 | Octreotide Sandostatin® | Palliative Care use only Oncology Acromegaly |
| 08.03.04.03 | Octreotide Sandostatin Lar® | Palliative Care use only Oncology Acromegaly |
| 06.04.01.01 | Oestrogel® | |
| 07.02.01 | Oestrogens, Topical Gynest® | |
| 07.02.01 | Oestrogens, Topical Estring® | |
| 07.02.01 | Oestrogens, Topical Ovestin® | |
| 07.02.01 | Oestrogens, Topical Vagifem® | |
| 08.02.03 | Ofatumumab Arzerra® | |
| 05.01.12 | Ofloxacin |
|
| 11.03.01 | Ofloxacin Eye drops 0.3% | |
| 01.07.03 | Oily phenol injection BP | |
| 04.02.01 | Olanzapine (oral) | |
| 04.02.02 | Olanzapine Embonate ZypAdhera® | The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer. HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED. |
| 08.01.05 | Olaparib Lynparza ® |
|
| 12.01.03 | Olive Oil Ear Drops | |
| 11.04.02 | Olopatadine Opatanol® | |
| 03.14 | Omalizumab Xolair® |
|
| 13.05.03 | Omalizumab | |
| 05.03.03.02 | Ombitasvir-paritaprevir-ritonavir Viekirax® | In line with NICE |
| 01.03.05 | Omeprazole | Capsules 10mg, 20mg Capsules are more cost effective than tablets Most brands of capsules can be opened and beads swallowed without crushing, or can be mixed with food or drink |
| 01.03.05 | Omeprazole dispersible Losec MUPS | Orodispersible tablets 10mg, 20mg ££- Orodispersible tablets are very significantly more expensive than capsules. For use in swallowing difficulties or via nasogastric tubes when beads in the capsule are too large and lansoprazole orodispersible are not acceptable (e.g. children with fine bore NG tubes). |
| 01.03.05 | Omeprazole IV | IV Infusion 40mg vial- Hospital use only |
| A5.07.05 | Omnistrip® | Adhesive wound closure strip Type of wound product is suitable for For atraumatic closure of minor wounds or surgical incisions Require a secondary dressing Duration dressing remains on wound before changing As necessary, up to 14 days Frequency of dressing change As necessary Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) None Rationale for inclusion in formulary Cost effective Essential for closure of minor injuries |
| 04.06 | Ondansetron | hyperemesis in pregnancy (off label) palliative care (off label) Chemotherapy |
| 04.09.01 | Opicapone Ongentys® | |
| 12.03.01 | Orabase Protective Paste | |
| 12.03.01 | Orahesive Powder | |
| 01.04 | Oral Rehydration Salts | Powder Follow Scriptswitch advice for most cost-effective prescribing option |
| 09.02.01.02 | Oral Rehydration Salts | |
| 04.05.01 | Orlistat capsules | Orlistat 60mg capsules - Over the counter preparation suitable for self-care/purchase if appropriate |
| 05.03.04 | Oseltamivir Tamiflu® | PHE guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza |
| 08.01.05 | Osimertinib | In line with NICE |
| 09.04.02 | Osmolite® |
|
| 09.04.02 | Osmolite®1.5 kcal |
|
| 09.04.02 | Osmolite®Plus |
|
| 09.05.02.02 | Osvaren® | |
| 08.01.05 | Oxaliplatin | |
| 06.04.03 | Oxandrolone Tablets 2.5 mg | |
| 04.01.02 | Oxazepam | |
| 04.08.01 | Oxcarbazepine | MHRA Advice Care should be taken when switching between oral formulations.The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with patient and/or carer, taking into account factors such as seizure frequency and treatment history. |
| 07.04.02 | Oxybutynin immediate release tablets | |
| 07.04.02 | Oxybutynin Modified release tablets | |
| 07.04.02 | Oxybutynin Hydrochloride patch Kentera® | |
| 13.12 | Oxybutynin immediate release tablets | |
| 04.07.02 | Oxycodone | |
| 04.07.02 | Oxycodone injection | |
| 03.06 | Oxygen | Short term use in palliative care Long term use- requires specialist assessment |
| 05.01.03 | Oxytetracycline | |
| 13.06.02 | Oxytetracycline | Please refer to Antimicrobial guidelines |
| 07.01.01 | Oxytocin | |
| 08.01.05 | Paclitaxel | |
| 08.01.05 | Paclitaxel - Albumin Bound Formulation Abraxane® | |
| 09.04 | Paediasure® |
|
| 09.04 | Paediasure® Plus |
|
| 09.04 | Paediasure® Plus Fibre |
|
| 09.04 | Paediasure® Peptide |
|
| 09.04 | Paediatric Seravit® |
|
| 09.06.07 | Paediatric Seravit® |
|
| 08.01.05 | Palbociclib Ibrance® | |
| 04.02.02 | Paliperidone Trevicta® | The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer. HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED. |
| 04.02.02 | Paliperidone Xeplion® | The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer. HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED. |
| 05.03.05 | Palivizumab Synagis® | |
| 04.06 | Palonosetron Aloxi® | |
| 01.09.04 | Pancreatin Pancrex® V | Powder Counsel patient on need for adequate hydration |
| 01.09.04 | Pancreatin Creon® products | Counsel patient on need for adequate hydration |
| 08.01.05 | Panitumumab Vectibix® | |
| 08.01.05 | Panobinostat Farydak®
| |
| 04.07.01 | Paracetamol | |
| 04.07.01 | Paracetamol | |
| 04.07.01 | Paracetamol Perfalgan® | |
| 04.07.01 | Paracetamol and codeine Co-codamol ®15/500 | |
| 04.07.01 | Paracetamol and codeine Co-codamol® 30/500 |
|
| 04.07.01 | Paracetamol and codeine Co-codamol ®15/500 | |
| 04.07.01 | Paracetamol and codeine Co-codamol® 30/500 | |
| 04.08.02 | Paraldehyde | |
| 06.06.01 | Parathyroid Hormone | |
| 05.04.05 | Paromomycin suspension | |
| 04.03.03 | Paroxetine tablets | |
| 09.04.01 | Pasta | Essential protein-free basic products. Necessary for children and adults with inborn errors of protein metabolism who tolerate very little natural protein. 100g pasta = 10g protein. |
| 08.01.05 | Pazopanib Votrient® | |
| 14.04 | Pediacel® | |
| 08.01.05 | Pegaspargase Oncaspar® | |
| 09.01.06 | Pegfilgrastim | |
| 08.02.04 | Peginterferon Alfa | |
| 08.01.05 | Pembrolizumab Keytruda® | |
| 08.01.03 | Pemetrexed Alimta® | |
| 04.02.01 | Penfluridol (Oral) | |
| 09.08.01 | Penicillamine | |
| 10.01.03 | Penicillamine | Supported by ESCA, see link below. |
| 11.03.01 | Penicillin 500o units in 1 ml eye drops | |
| 05.04.08 | Pentamidine Isetionate Pantacarinat® | |
| 01.02 | Peppermint Oil | Capsule E/C 0.2ml |
| 01.02 | Peppermint water | unlicensed For specialist use only |
| 01.01.02 | Peptac | Suspension |
| 09.04.02 | Peptamen® |
|
| 09.04 | Peptamen® Junior |
|
| 09.04 | Peptamen® Junior |
|
| 09.04 | Peptamen® Junior Advance |
|
| 09.04.02 | Peptamen®AF | |
| 09.04.02 | Peptamen®HN |
|
| 04.08.01 | Perampanel tablets | MHRA Advice When prescribing for epilepsy the patient should be assessed to make a clinical judgement if the same manufacturer’s product/brand is necessary taking into account factors such as seizure frequency and treatment history. Also take into account patient/carer-related factors such as their negative perceptions about alternative products and/or other issues related to the patient such co-morbid autism, mental health issues, or learning disability. |
| 02.06.03 | Perhexiline tablets | |
| 04.02.01 | Pericyazine (oral) |
|
| 02.05.05.01 | Perindopril erbumine tablets | |
| 13.10.04 | Permethrin 5% Lyclear® Dermal Cream | Over the counter preparation suitable for self-care/purchase if appropriate |
| 04.02.01 | Perphenazine (oral) |
|
| 08.01.05 | Pertuzumab Perjeta® | In line with NICE |
| 04.07.02 | Pethidine injection | |
| 02.08.02 | Phenindione tablets | |
| 04.08.01 | Phenobarbital | MHRA Advice Patients being treated for epilepsy should be maintained on a specific manufacturer's product. |
| 13.14.07 | Phenol 2% w/w in compound zinc paste BP | |
| 02.05.04 | Phenoxybenzamine Hydrochloride capsules | Check availibility |
| 05.01.01.01 | Phenoxymethylpenicillin oral presentations | |
| 02.07.02 | Phenylephrine | |
| 11.05 | Phenylephrine Hydrochloride Minims® Phenylephrine Hydrochloride | |
| 04.08.01 | Phenytoin | MHRA Advice Patients being treated for epilepsy should be maintained on a specific manufacturer's product. |
| 09.04 | Phlexy-10® Exchange System |
|
| 09.04 | Phlexy-Vits® |
|
| 03.09.01 | Pholcodine Linctus, BP | Over the counter preparation suitable for self-care/purchase if appropriate |
| 09.05.02.01 | Phosphate supplements Phosphate-Sandoz® | |
| 01.06.04 | Phosphates (Rectal) Fletchers phosphate enema, fleet ready to use enema | Enema |
| 09.06.06 | Phytomenadione Konakion® MM | |
| 09.06.06 | Phytomenadione Konakion® MM Paediatric | |
| 09.06.06 | Phytomenadione 1mg | |
| A5.06.01 | PICO products | Disposable and portable system designed to kick start wound healing. Required components: One PICO device, 2 dressings per kit. Type of wound product is suitable for Acute, chronic, dehisced, partial thickness burns, flaps, grafts and traumatic wounds. Consider standard interactive dressings first. Duration dressing remains on wound before changing Twice a week dressing change, PICO device weekly change Frequency of dressing change Determined by exudate levels. Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) It should not be used on: Confirmed and untreated osteomyelitis Malignancy in wound bed or wound margins Exposed blood vessels Organs Unexplored fistulae Necrotic wounds Anastomotic sites Emergency airway aspiration Pleural, mediastinal or chest tube drainage and surgical suction Rationale for inclusion in formulary These devices promote patient mobility at a cost effective price and is available on drug tariff which other comparable models are not. |
| 01.06.05 | Picolax® | Oral powder |
| 11.06 | Pilocarpine 1%,2% and 4% eye drops | |
| 12.03.05 | pilocarpine Hydrochloride tablets Salagen® | |
| 11.06 | Pilocarpine preservative free | |
| 13.05.03 | Pimecrolimus Elidel® | |
| 06.01.02.03 | Pioglitazone | |
| 05.01.01.04 | Piperacillin and Tazobactam | |
| 04.09.03 | Piracetam | |
| 04.02.03 | Pirenzipine (unlicensed) | Hospital only |
| 03.11 | Pirfenidone Esbriet® | Hospital only - NHSE commissioned |
| 05.01.01.05 | Pivmecillinam Hydrochloride |
|
| 04.07.04.02 | Pizotifen | |
| 09.04.01 | Pizza bases | Important protein-free foods to provide important energy, assist dietary adherence and provide variety when natural protein tolerance is very limited. Necessary for children and adults with inborn errors of protein metabolism who do not tolerate very little natural protein. One regular pizza likely to provide 20g + protein. |
| 09.04 | PKU Air 15 |
|
| 09.04 | PKU Air 20 |
|
| 09.04 | PKU Anamix first spoon |
|
| 09.04 | PKU Anamix® Infant |
|
| 09.04 | PKU cooler 10® |
|
| 09.04 | PKU cooler 15® |
|
| 09.04 | PKU cooler 20® |
|
| 09.04 | PKU express15® |
|
| 09.04 | PKU express20® |
|
| 09.04 | PKU gel® |
|
| 09.04 | PKU Lophlex |
|
| 09.04 | PKU Lophlex® LQ 10 |
|
| 09.04 | PKU Lophlex® LQ 20 |
|
| 09.04 | PKU Sphere 15 | A low phenylalanine supplement derived from whey protein for children and adults with phenylketonuria. It is more palatable than amino acid supplements and associated with better utilisation of protein. Very useful for adult patients trying to return to diet or children / adults struggling to take their amino acid product because of its taste. Suitable from aged 4 years |
| 09.04 | PKU Sphere 20 | A low phenylalanine supplement derived from whey protein for children and adults with phenylketonuria. It is more palatable than amino acid supplements and associated with better utilisation of protein. Very useful for adult patients trying to return to diet or children / adult struggling to take their amino acid product because of its taste. Suitable from aged 4 years |
| 09.04 | PKU Start® |
|
| 14.04 | Pneumococcal polysaccharide conjugate vaccine (adsorbed) Synflorix® | |
| 14.04 | Pneumococcal polysaccharide conjugate vaccine (adsorbed) Prevenar 13® | |
| 13.07 | Podophyllotoxin Condyline® | |
| 13.07 | Podophyllotoxin Warticon® | |
| 13.07 | Podophyllum | |
| 14.04 | Poliomyelitis Vaccine Inactivated (Salk) | The polio vaccine is only given as part of combined products: ● diphtheria/tetanus/acellular pertussis/inactivated polio vaccine/ Haemophilus influenzae type b (DTaP/IPV/Hib) ● diphtheria/tetanus/acellular pertussis/inactivated polio vaccine (DTaP/ IPV or dTaP/IPV) ● tetanus/diphtheria/inactivated polio vaccine (Td/IPV). |
| 09.04 | Polycal® |
|
| A5.07.01 | Polyfield Nitrile Patient Pack primary care and BCHC, other Trusts as per contract | Sterile dressing pack Type of wound product is suitable for To be used on all wounds requiring aseptic dressing procedures Duration dressing remains on wound before changing Single use Frequency of dressing change Determined by wound type Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) None listed Rationale for inclusion in formulary Available on drug tariff, cost effective and incorporates a measure guide which would be an additional cost with other packs |
| A5.02.05 | PolyMem | Foam dressing that contains a cleansing agent and glycerol Type of wound product is suitable for Low to moderately exuding wound including skin tears, and other traumatic wounds, superficial and partial thickness wounds, burns, donor and graft sites and radiotherapy induces reactions Duration dressing remains on wound before changing 2-7 days Frequency of dressing change Up to 7 days dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Sensitivity to ingredients contained within the dressing Not for full thickness burns Not for ischaemic wounds Not for diabetic foot wounds Not in conjunction with solutions containing hypochlorite Rationale for inclusion in formulary Suitable for fragile and sensitive skin, Soft and comformable, Easy to redress awkward areas Wide range of sizes including digit shaped dressings |
| 14.04 | Polysaccharide vaccine for injection Typhim Vi®, Typherix® | |
| 14.04 | Polysaccharide vaccine with hepatitis A vaccine | |
| 09.02.01.01 | Polystyrene Sulphonate Resins Resonium A® | |
| 09.02.01.01 | Polystyrene Sulphonate Resins Calcium Resonium® | |
| 13.09 | Polytar Plus® |
Over the counter preparation suitable for self-care/purchase if appropriate |
| 13.09 | Polytar® |
Over the counter preparation suitable for self-care/purchase if appropriate |
| 08.01.05 | Ponatinib Iclusig® | In line with NICE |
| 03.05.02 | Poractant Alfa Curosurf® | Hospital only |
| 05.02 | Posaconazole | |
| 09.05.02.01 | Potassium acid phosphate | |
| 09.02.01.01 | Potassium Chloride efferevescent tablets Sando-K® | |
| 09.02.01.01 | Potassium Chloride MR tablets Slow-K® | |
| 09.02.01.01 | Potassium Chloride SF syrup Kay-Cee-L® | |
| 07.04.03 | Potassium Citrate | |
| 13.11.06 | Potassium Permanganate tablets | |
| 13.11.04 | Povidone-Iodine preparations | |
| 04.09.01 | Pramipexole IR tablets | |
| 02.09 | Prasugrel Efient® | |
| 02.12 | Pravastatin tablets | |
| 05.05.05 | Praziquantel tablets | |
| 01.05.02 | Prednisolone | Tablets 5mg, EC 2.5mg, 5mg, Soluble 25mg Plain tablets are first line option. EC tablets are more expensive than plain tablets without any substantial evidence that they confer any GI benefits 25mg tablets are more expensive per mg than 5mg tablets. Soluble tablets are significantly more expensive than normal tablets which can be crushed & dispersed (unlicensed). For short term use in acute exacerbation or 'flare-ups'of relevant conditions |
| 01.05.02 | Prednisolone | Retention Enema (20mg/100ml single dose pack, Predsol®) Foam Enema ££- Predfoam® discontinued, generic replacement is very expensive Suppositories - (5mg, Predsol®) For short term use in acute exacerbation or 'flare-ups'of relevant conditions |
| 06.03.02 | Prednisolone | |
| 10.01.02.01 | Prednisolone | |
| 10.01.02.01 | Prednisolone | for use in children or patients with swallowing difficulties |
| 11.04.01 | Prednisolone 0.5% eye drops | |
| 11.04.01 | Prednisolone 1% eye drops Pred Forte® | |
| 11.04.01 | Prednisolone preservative free eye drops 0.5% | |
| 03.12 | Prednisolone tablets | |
| 10.01.04 | Prednisolone tablets | Second line gout treamtment |
| 04.03.04 | Pregabalin |
Schedule 3 Controlled Drug as of 01/04/2019 |
| 04.07.03 | Pregabalin |
Schedule 3 Controlled Drug as of 01/04/2019 |
| 04.08.01 | Pregabalin |
Schedule 3 Controlled Drug as of 01/04/2019 |
| 06.04.01.01 | Premarin® | |
| 06.04.01.01 | Premique® low dose | |
| 05.04.01 | Primaquine | |
| 04.08.01 | Primidone | MHRA Advice Patients being treated for epilepsy should be maintained on a specific manufacturer's product. |
| 04.09.03 | Primidone | |
| 10.01.04 | Probenecid | |
| 05.01.01.01 | Procaine Penicillin G Injection | |
| 09.04 | Pro-Cal® Shot |
|
| 09.04 | Pro-Cal® Singles |
|
| 08.01.05 | Procarbazine | |
| 04.06 | Prochlorperazine | |
| 04.02.03 | Procyclidine | |
| 04.09.02 | Procyclidine | |
| 04.09.02 | Procyclidine | |
| 13.10.05 | Proflavine Cream, BPC | Hospital only |
| 06.04.01.02 | Progesterone Crinone® | |
| 06.04.01.02 | Progesterone Cyclogest® | Recurrent miscarriage (off label use) Fertility (off label use) |
| 06.04.01.02 | Progesterone (micronised) Utrogestan® | |
| 05.04.01 | Proguanil Hydrochloride | |
| 05.04.01 | Proguanil Hydrochloride with Atovaquone | |
| 06.04.01.01 | Progynova® |
|
| 03.04.01 | Promethazine | |
| 04.06 | Promethazine Hydrochloride | |
| 04.01.01 | Promethazine Hydrochloride | |
| A5.03.04 | Prontosan Wound Gel 30ml | A gel containing betaine, a surfactant to remove biofilm and debris and PHMB to help control bacterial bioburden. Type of wound product is suitable for Cleansing, decontamination and moisturising of acute and chronic wounds including 1st and 2nd degree burns. Duration dressing remains on wound before changing Apply at each dressing change Frequency of dressing change As determined by the wound and exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) None Rationale for inclusion in formulary Gel to cleanse and decontaminate wounds Antimicrobial Breaks down biofilms in chronic wounds |
| A5.03.04 | Prontosan Wound Irrigation Solution | Wound irrigation solution containing betaine a surfactant to remove biofilm and debris and PHMB to help control bacterial bioburden. Type of wound product is suitable for Cleansing, decontamination and moisturising of acute and chronic wounds including 1st and 2nd degree burns. Duration dressing remains on wound before changing Apply at each dressing change Frequency of dressing change As determined by the wound and exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) None Rationale for inclusion in formulary Solution to cleanse and decontaminate wounds Antimicrobial Breaks down biofilms in chronic wounds Can be used as an irrigation fluid with VAC Veraflow |
| A5.12 | Prontosan Wound Irrigation solution | See under antimicrobials |
| 02.03.02 | Propafenone hydrochloride | |
| 13.12 | Propantheline | |
| 02.04 | Propranolol | |
| 04.07.04.02 | Propranolol | |
| 04.09.03 | Propranolol | |
| 13.14.01 | Propylene glycol 20% w/w in aqueous cream | |
| 13.14.02 | Propylene glycol 40% w/w in Dermovate® cream | |
| 06.02.02 | Propylthiouracil | |
| A5.15 | Proshield plus ® | Skin protectant Type of wound product is suitable for To treat injured skin associated with incontinence where a dressing seal cannot be achieved Frequency of use Apply at each episode of hygiene Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) External use only Avoid contact with eyes Known allergic sensitivity to any of the components Keep out of reach of children Do not apply to pressure ulcers or leg ulcers Not to be used as a first line barrier cream Not to be used to protect peri wound Not to be used as an emollient Rationale for inclusion in formulary For treatment of incontinence lesions where a standard dressing seal cannot be achieved |
| A5.15 | ProShield® | Skin cleanser for use in patients with chronic diarrhoea or incontinence of urine. Type of wound product is suitable for To cleanse intact or injured skin from contamination of urine or faeces Frequency of use Apply at each episode of hygiene Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) External use only Avoid contact with eyes Known allergic sensitivity to any of the components Keep out of reach of children Rationale for inclusion in formulary For skin cleansing related to incontinence. Only skin cleanser available on drug tarrif |
| 09.04 | Prosource® Jelly |
|
| 09.04 | Prosource® Liquid |
|
| 09.04 | ProSource® Plus |
|
| 09.04 | ProSource® TF |
|
| 02.08.03 | Protamine Sulphate | |
| 02.11 | Prothrombin complex injection | |
| 09.04 | Protifar® |
|
| 06.05.01 | Protirelin TRH | |
| 09.04 | ProZero® |
|
| 01.06.07 | Prucalopride Resolor ® | Available for use in men and women for chronic constipation. |
| 03.10 | Pseudoephedrine Hydrochloride | Over the counter preparation suitable for self-care/purchase if appropriate |
| 05.01.09 | Pyrazinamide | Pyrazinamide liquid 500mg in 5ml (unlicensed) |
| 10.02.01 | Pyridostigmine Bromide | |
| 09.06.02 | Pyridoxine Hydrochloride | |
| 05.04.01 | Pyrimethamine Darprim® | |
| 04.02.01 | Quetiapine Modified-release preparations | APC preferred brands Biquelle XL, Sondate XL, Zaluron XL Choose most cost-effective option. |
| 04.02.01 | Quetiapine tablets | |
| 06.07.01 | Quinagolide | |
| 05.04.01 | Quinine dihydrochloride | |
| 05.04.01 | Quinine sulphate | |
| 10.02.02 | Quinine sulphate | Short term use only- MHRA guidance |
| 14.05 | Rabies immunoglobulin | |
| 16.02 | Radium-223 Xofigo® | |
| 06.04.01.01 | Raloxifene Hydrochloride | In line with NICE
|
| 05.03.01 | Raltegravir Isentress ® | |
| 08.01.03 | Raltitrexed Tomudex® | |
| 02.05.05.01 | Ramipril capsules | |
| 11.08.02 | Ranibizumab Lucentis® | |
| 01.03.01 | Ranitidine | Prescribe standard release tablets only; modified release (MR) preparations are non-formulary |
| 01.03.01 | Ranitidine Effervescent tablet | For use in patients with swallowing difficulties or via nasogastric tubes only |
| 01.03.01 | Ranitidine IV | Injection 50mg/2ml For specialist use only |
| 02.06.03 | Ranolazine Ranexa® | Supported by RICaD, see link below. |
| 04.09.01 | Rasagiline Azilect® |
|
| 13.14.07 | Reflectant (Dundee) sunscreens | coffee, coral pink, beige |
| 08.01.05 | Regorafenib Stivarga® | |
| 01.01 | Remote Control Panasonic® | Control the TV and costs £20 to replace MR tabs restricted for use in xyz |
| 09.04 | Renapro® |
|
| 09.04 | Renapro® shot |
|
| 09.04 | Renastart® |
|
| 09.04 | Renastart® |
|
| A5.06.01 | Renasys products | The use of sub atmospheric pressure to promote or assist wound healing or to remove fluids from a site. Required components: Pump, Dressings foam or gauze, tubing and canister. Type of wound product is suitable for Acute, chronic and traumatic wounds. Can be used as a adjunct to surgery and for salvage procedures such as wound dehiscence. Benefits are that it removes excess fluid that may contain bacterial pathogens, reduces soft tissue oedema, promotes granulation and provides a moist wound healing environment. Consider standard interactive dressings first. Duration dressing remains on wound before changing Every three days Frequency of dressing change Determined by exudate levels. Different canister sizes available Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) It should not be used on: Grossly infected or bleeding wounds Malignancy Exposed blood vessels Organs Unexplored fistulae Extensive necrotic wounds Caution with foam, document the number inserted, ensure all pieces are retrieved. Rationale for inclusion in formulary It removes excess fluid that may contain bacterial pathogens, reduces soft tissue oedema, promotes granulation and provides a moist wound healing environment. Both companies products are included due to different contracting arrangements. Can be used on large open wounds to increase speed of wound healing |
| 09.06.07 | Renavit® |
|
| 09.04 | Renilon® 7.5 |
|
| 06.01.02.03 | Repaglinide | |
| 14.04 | Repevax® | |
| 03.14 | Reslizumab Cinqaero® |
|
| 09.04 | Resource® Junior |
|
| 09.04 | Resource® Optifibre |
|
| 09.09 | Resource® ThickenUp Clear |
|
| 09.04.02 | Resource®Energy |
|
| 02.10.02 | Reteplase | |
| 14.04 | Revaxis® | |
| 05.03.05 | Ribavirin | |
| 08.01.05 | Ribociclib Kisqali® | |
| 09.06.02 | Riboflavin | |
| 05.01.09 | Rifabutin | |
| 05.01.09 | Rifampicin infusion | |
| 05.01.09 | Rifampicin oral presentations | |
| 13.06.02 | Rifampicin | |
| 05.01.09 | Rifampicin and Isoniazid Rifinah® 300 | |
| 05.01.09 | Rifampicin and Isoniazid Rifinah® 150 | |
| 05.01.09 | Rifampicin and Isoniazid and Pyrazinamide Rifater® | |
| 05.01.09 | Rifampicin with ethambutol, isoniazid and pyrazinamide Voractiv® | |
| 05.01.07 | Rifaximin | |
| 05.03.01 | Rilpivirine hydrochloride Edurant® | |
| 04.09.03 | Riluzole Rilutek® | |
| 06.06.02 | Risedronate |
|
| 04.02.02 | Risperidone Risperdal Consta® | The APC's view is that, on clinical grounds, the status of antipsychotic depot injections should be amber with a framework in place in Primary Care before transfer. HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED. |
| 04.02.01 | Risperidone (oral) | |
| 05.03.01 | Ritonavir Norvir® | |
| 08.02.03 | Rituximab | |
| 10.01.03 | Rituximab (rheumatology) MabThera® | Hospital only |
| 02.08.02 | Rivaroxaban
| APC preferred agent: this recommendation must only be taken into account after a patient and prescriber have discussed all treatment options (including warfarin) and only if they have no preference about which medicine they want to use. Following diagnosis of AF- use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD. RICaD: Rivaroxaban in AF For the treatment and secondary prevention of DVT and/or PE - use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD. RICaD: Rivaroxaban in DVT /PE For preventing adverse outcomes after acute management of ACS (TA335) use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD.RICaD: Rivaroxaban post ACS Use following Hip and Knee surgery- full course of treatment supplied on discharge. |
| 04.11 | Rivastigmine | The APC's view is that on clinical grounds, the status of these drugs for dementia should be amber, with a framework in place in primary care before transfer. HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED. |
| 04.07.04.01 | Rizatriptan | Tablets Orodispersible tablets SF- reserve for patients who are vomiting due to migraine Wafer/oral lyophilisates SF £££ |
| 03.03.03 | Roflumilast Daxas® | In line with NICE |
| 09.01.04 | Romiplostim Nplate® | |
| 04.09.01 | Ropinirole M/R tablets |
|
| 04.09.01 | Ropinirole tablets |
|
| 02.12 | Rosuvastatin tablets | |
| 14.04 | Rotavirus vaccine Rotarix® | |
| 04.09.01 | Rotigotine patches | |
| 04.08.01 | Rufinamide | MHRA advises that when prescribing for epilepsy the patient should be assessed to make a clinical judgement if the same manufacturer’s product/brand is necessary taking into account factors such as seizure frequency and treatment history. Also take into account patient/carer-related factors such as their negative perceptions about alternative products and/or other issues related to the patient such co-morbid autism, mental health issues, or learning disability. |
| 08.01.05 | Ruloxitinib Jakavi® | |
| 09.04 | S.O.S® |
|
| 02.05.05 | Sacubitril valsartan Entresto ® | |
| 03.01.01.01 | Salbutamol | |
| 07.01.03 | Salbutamol | |
| 03.01.01.01 | Salbutamol IV | |
| 13.07 | Salicylic Acid Salatac® | Over the counter preparation suitable for self-care/purchase if appropriate |
| 13.14.06 | Salicylic acid 10% w/w in emulsifying ointment | |
| 13.07 | Salicylic Acid 16.7% with Lactic Acid 16.7% Salactol® | Over the counter preparation suitable for self-care/purchase if appropriate |
| 13.14.06 | Salicylic acid 2% w/w and sulphur 2% w/w in aqueous cream | |
| 13.14.06 | Salicylic acid 2% w/w in emulsifying ointment | |
| 13.14.06 | Salicylic acid 20% w/w in emulsifying ointment | |
| 13.14.02 | Salicylic acid 5% w/w / propylene glycol 47.5% w/w in Dermovate® cream | |
| 13.07 | Salicylic Acid Ointment Verrugon® | Over the counter preparation suitable for self-care/purchase if appropriate |
| 12.03.05 | Saliveze® Oral spray | Approved for |
| 12.03.05 | Salivix® pastilles | Approved for |
| 03.01.01.01 | Salmeterol | |
| 09.05.01.01 | Sandocal-1000® | |
| 06.04.01.01 | Sandrena® gel | |
| 09.04.01 | Sapropterin Dihydrochloride Kuvan® | |
| 05.03.01 | Saquinavir Invirase® | |
| 08.02.04 | Sarilumab Kevzara® | |
| 09.04.01 | Savoury meals and mixes | Important protein-free foods to provide important energy, assist dietary adherence and provide variety when natural protein tolerance is very limited. Necessary for children and adults with inborn errors of protein metabolism who tolerate very little natural protein-. 1 ordinary meal is likely to provide ≥25g protein. |
| 09.04 | Scandishake® Mix |
|
| 01.07.02 | Scheriproct® suppositories | Scheriproct ointment and suppositories |
| A5.11 | Seal-Tight Wound care protector | Waterproof protector, non slip latex free Type of wound product is suitable for Used to keep leg and foot dressings dry, can be fully submerged in water Rationale for inclusion in formulary Multiple sizing for leg including extra large limb No adjustments required |
| 13.05.02 | Sebco® | |
| 13.05.03 | Secukinumab | |
| 04.09.01 | Selegiline Hydrochloride |
|
| 09.05.05 | Selenium capsules/tablets Selenase® | |
| 13.09 | Selenium Sulphide Selsun® | Over the counter preparation suitable for self-care/purchase if appropriate |
| 01.06.02 | Senna | Tablets 7.5mg; Syrup 7.5mg/5ml - Syrup is currently more cost effective than tablets - Time to effect approximately 8 to 12 hours |
| 04.03.03 | Sertraline tablets | |
| 09.05.02.02 | Sevelamer | |
| 02.05.01 | Sildenafil Revatio® | NHS England commissioned |
| 07.04.05 | Sildenafil tablets GENERIC | For use in digital ulceration, see chapter 10 |
| 10.04 | Sildenafil tablets GENERIC | |
| A5.16 | Silver nitrate | NOT 1ST LINE TREATMENT ONLY TO BE USED IN A CLINIC SETTING OR BY A CLINICAL SPECIALIST Type of wound product is suitable for For treatment of chronic overgranulation, non acute or weeping. Duration product remains on wound before changing Apply moistened caustic pencil tip for 1-2 mins, whilst protecting the surrounding skin with soft paraffin. Frequency of use Maximum treatment: 3 applications Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Keep away from the eyes Not suitable for use on the face, ano-genital region or large areas Not for untreated bacterial, fungal or viral skin lesions Can cause chemical burns Rationale for inclusion in formulary Treatment of overgranulation |
| 13.07 | Silver Nitrate 95% with Potassium Nitrate 5% AVOCA® | Over the counter preparation suitable for self-care/purchase if appropriate |
| 13.07 | Silver Nitrate applicators ( 40% ,75% and 95%) | Over the counter preparation suitable for self-care/purchase if appropriate |
| 13.07 | Silver Nitrate caustic applicator | |
| 13.10.01.01 | Silver Sulfadiazine Flamazine® | |
| A5.17 | silver sulfadiazine 1% Flamazine® | Type of wound product is suitable for Partial thickness & full thickness burn injuries. Sloughy burn wounds or areas of graft loss Duration preparation remains on wound before changing 24-48 hours Frequency of use Daily- occasionally alternate day Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Allergy to any ingredients. Not to use in pregnancy or breast feeding Take care if: suffer kidney or liver problems, deficiency of the enzyme known as glucose 6- phosphate dehydrogenase. Taking tablets prescribed for epilepsy Rationale for inclusion in formulary Prevent and treat bacterial infections in burns, skin graft donor sites. |
| A5.17 | Silver sulfadiazine 1.0g & Cerium nitrate 2.2g Flammercerium® | Type of wound product is suitable for Partial thickness & full thickness burn injuries. Duration preparation remains on wound before changing 24-48 hours Frequency of use Daily- occasionally alternate day Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Allergy to any ingredients. Not to use in pregnancy or breast feeding, infants or babies under the age of 2 years. Take care if: suffer kidney or liver problems, deficiency of the enzyme known as glucose 6- phosphate dehydrogenase. Taking tablets prescribed for epilepsy Rationale for inclusion in formulary Prevent and treat bacterial infections in burns |
| 01.01.01 | Simeticone |
|
| 09.04 | Similac® Alimentum |
|
| 03.09.02 | Simple Linctus, BP | Over the counter preparation suitable for self-care/purchase if appropriate |
| 03.09.02 | Simple Linctus, Paediatric BP | Over the counter preparation suitable for self-care/purchase if appropriate |
| 02.12 | Simvastatin tablets | |
| 08.02.02 | Sirolimus Rapamune® | Post transplant- new patients Post transplant-patients initiated pre April 2013 |
| 06.01.02.03 | Sitagliptin Januvia® | In line with NICE |
| 09.04 | Slo drinks milkshakes |
|
| 09.09 | SLO Drinks® |
|
| 09.04 | SMA LF® Lactose Free Formula (previous name SMA® LF) |
|
| 09.04.02 | SMA® PRO Gold Prem 2 | Child under 12 years
|
| 09.04.02 | SMA® PRO High Energy | Child under 12 years
|
| 10.01.03 | Sodium Aurothiomalate Myocrisin® | Supported by ESCA, see link below. |
| 07.04.03 | Sodium Bicarbonate | |
| 12.01.03 | Sodium Bicarbonate 5% ear drops | |
| 09.02.01.03 | Sodium Bicarbonate capsules | |
| 03.01.05 | Sodium Chloride | |
| 09.02.01.02 | Sodium Chloride |
|
| 11.08.01 | Sodium Chloride Minims® Saline | |
| 03.07 | Sodium chloride 0.9% | |
| 07.04.04 | Sodium Chloride 0.9% Catheter Patency Solutions | |
| 13.11.01 | Sodium Chloride 0.9% irrigation sachets | |
| 11.08.01 | Sodium Chloride 0.9% Solutions | |
| 11.08.01 | Sodium Chloride 5% eye ointment | |
| 11.08.01 | Sodium Chloride 5% PF drops Moorfields | |
| 12.02.02 | Sodium Chloride Nose drops 10ml | |
| 07.04.04 | Sodium Citrate | Hospital only |
| 01.06.04 | Sodium Citrate (Rectal) | Micro-enema Microlette®, Relaxit® and Micralax® |
| 06.06.02 | Sodium Clodronate | |
| 11.04.02 | Sodium Cromoglicate 2% eye drops | |
| 11.04.02 | Sodium Cromoglicate 2% eye drops preservative free | |
| 09.01.01.01 | Sodium Feredetate SF Elixir Sytron® | |
| 09.05.03 | Sodium Fluoride Mouthwash, BP | |
| 09.05.03 | Sodium Fluoride Toothpaste 0.619%, DPF | |
| 09.05.03 | Sodium Fluoride Toothpaste 1.1%, DPF | |
| 11.08.01 | Sodium Hyaluronate 0.15% Multi Hyabak® | |
| 11.08.01 | Sodium Hyaluronate 0.2% eye drops PF Evolve HA ® |
Approved onto formulary January 2019 |
| 11.08.01 | Sodium Hyaluronate 0.2% PF Multi Hylo-Forte® | |
| 11.08.01 | Sodium Hyaluronate 0.4% SDU Clinitas® | |
| 02.05.01 | Sodium nitroprusside | Injection (Secondary Care only) |
| 02.13 | Sodium Tetradecyl Sulphate Fibro-Vein® | |
| 04.08.01 | Sodium Valproate |
Contraindicated in women of childbearing potential unless part of the Pregnancy Prevention Programme. See MHRA guidance |
| 04.08.01 | Sodium Valproate Episenta® |
Contraindicated in women of childbearing potential unless part of the Pregnancy Prevention Programme. See MHRA guidance |
| 05.03.03.02 | Sofosbuvir-velpatasvir-voxilaprevir | Hospital only - NHSE commissioned In line with NICE |
| A5.01.02 | Softpore - self adhesive | Type of wound product is suitable for Low to moderately exuding wounds, superficial wounds (closed), light amounts of exudate. Use alone without other products, also can be used as a protective dressing for sutured post operative wounds. Can be used as a protective dressing for newly epithelialised wounds. Can be used for minor traumatic wounds Duration dressing remains on wound before changing Maximum 7 days, dependent on exudate levels Frequency of dressing change If daily change is required; review dressing type Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Known product or component sensitivity Rationale for inclusion in formulary Sutured/Post-surgical wound for protection . Most cost effective option. Can be used as a protective dressing for newly epithelialized wounds. Can be used for minor traumatic wounds |
| 07.04.02 | Solifenacin Vesicare® | |
| 06.05.01 | Somatropin | |
| 08.01.05 | Sorafenib Nexavar® | |
| A5.02.06 | Sorbsan range | Calcium alginate dressing Type of wound product is suitable for Use in moderate to highly exuding wounds with a sloughy or granulating wound bed. Also helps with haemostasis in wounds with minor bleeding or where blood is present in the exudate. Available in flat and rope dressing Primary dressing only. Secondary dressing will be required. Duration dressing remains on wound before changing Can be left in place for approximately 4 days Frequency of dressing change 1-4 days dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Do not use in individuals with a known sensitivity to any of the components of the dressing Do no use on dry or lightly exuding wounds as adherence is an issue Extreme caution if used for tumours with friable tissue Rationale for inclusion in formulary Sorbsan can facilitate debridement, absorb exudate and is a haemostat Cost effective Biodegradable |
| 02.04 | Sotalol | Anti Arrhythmic |
| 07.03.03 | Spermicidal Contraceptives Gygel®2% | |
| 05.04.07 | Spiramycin | |
| 02.02.03 | Spironolactone tablets | |
| 09.04.01 | Spreads | Important protein-free foods to provide important energy, assist dietary adherence and provide variety when natural protein tolerance is very limited. Necessary for children and adults with inborn errors of protein metabolism who tolerate very little natural protein. 1 portion ordinary spread likely to provide 2-5g protein. |
| 01.04 | St Mark’s powder | Unlicensed Specialist use only |
| 01.04 | St Mark’s recipe | For fluid and electrolyte replacement following diarrhoea |
| 03.01.05 | Standard range peak flow meter | |
| 05.03.01 | Stavudine Zerit® | |
| A5.05.01 | Sterile Gauze swabs 7.5cmx7.5cm ONLY | 7.5cm x 7.5cm only Type of wound product is suitable for Cleansing wounds via aseptic technique Duration dressing remains on wound before changing N/A Frequency of dressing change N/A Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Not to be applied to a wound as a dressing Cost effective Included in Sterile wound packs or used to supplement sterile packs |
| 04.08.01 | Stiripentol Diacomit® | Severe myoclonic epilepsy in infancy (Dravet syndrome) APC supports use in Adults: for continuation of therapy started in childhood. (Note Off Label use in adults) |
| 02.10.02 | Streptokinase | |
| 05.01.09 | Streptomycin Sulphate | |
| 01.03.03 | Sucralfate Antepsin® | Tablet 1g, Suspension 500mg/5ml For specialist use only |
| 09.05.02.02 | Sucroferric oxyhydroxide Velphoro® | 2nd or 3rd line agent Specialist use only |
| A5.15 | Sudocrem ® | Barrier cream Type of wound product is suitable for Intact skin, not to be applied to a wound. To protect the skin from moisture, irritation and chafing. To protect the peri wound when utilising free range larvae Frequency of use Application at every episode of hygiene. Apply a thin layer sparingly. Remove with olive oil. Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Not to be used in conjunction with containment products for incontinence due to the inclusion of lanolin in the ingredients, which will repel urine/faeces back onto the skin. Any allergy to the listed ingredients Rationale for inclusion in formulary Dermatology approved |
| 13.02.02 | Sudocrem® |
Over the counter preparation suitable for self-care/purchase if appropriate |
| 05.01.08 | Sulfadiazine | |
| 01.05.01 | Sulfasalazine | Plain tablets are more cost effective than enteric coated tablets. |
| 10.01.03 | Sulfasalazine | Supported by ESCA, see link below. |
| 10.01.01 | Sulindac | |
| 04.02.01 | Sulpiride (oral) | |
| 04.07.04.01 | Sumatriptan | |
| 08.01.05 | Sunitinib Sutent® | |
| 13.08.01 | Sunsense® Ultra | Non-formulary if not for ACBS approved indication |
| A5.02.03 | Suprasorb X | Biocellulose gel sheet dressing Type of wound product is suitable for Light to moderately, non infected exuding wounds Duration dressing remains on wound before changing 1-7 days Frequency of dressing change 1-7 days, dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Known sensitivity to any components of the dressing Rationale for inclusion in formulary Light to moderate exudate. |
| A5.03.04 | Suprasorb X + PHMB | Biocellulose gel sheet dressing with PHMB antimicrobial properties Type of wound product is suitable for Light to moderately, critically colonised or infected exuding wounds Can be used on all wound types at all stages of wound healing Can be cut or folded to wound shape size Duration dressing remains on wound before changing 1-3 days Frequency of dressing change 1-3 days, dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Known sensitivity to PHMB or any components of the dressing Heavily exuding wounds Rationale for inclusion in formulary Light to moderate exudate in clinically infected wounds. Suitable for all wounds at all stages of wound healing Doesn’t affect healthy cells, suitable for long term use when necessary Specialist recommendation |
| 04.13 | Tacrolimus | Specialist use only for neurological conditions |
| 08.02.02 | Tacrolimus | Prescribe by brand name only to minimise the risk of inadvertent switching between products, which has been associated with reports of toxicity and graft rejection (June 2012) Post transplant- new patients Post transplant-patients initiated pre April 2013 |
| 08.02.02 | Tacrolimus | Prescribe by brand name only to minimise the risk of inadvertent switching between products, which has been associated with reports of toxicity and graft rejection (June 2012) Post transplant- new patients Post transplant-patients initiated pre April 2013 |
| 13.05.03 | Tacrolimus Protopic® | |
| 13.14.07 | Tacrolimus 0.1% w/w in OrabaseTM | |
| 13.14.07 | Tacrolimus 0.3% w/w in OrabaseTM | |
| 07.04.05 | Tadalafil tablets 10mg, 20mg ONLY |
|
| 11.06 | Tafluprost (Preservative Free) 15micrograms/ml | |
| 08.01.05 | Talimogene laherparepvec Imlygic® |
|
| 08.03.04.01 | Tamoxifen | |
| 07.04.01 | Tamsulosin M/R capsules | |
| 04.07.02 | Tapentadol Palexia® | |
| 13.05.02 | Tars - bath preparations Psoriderm emulsion® | |
| 02.08.01 | TauroLock TauroLock HEP 500 ® | |
| A5.02.05 | Tegaderm Foam Adhesive | Type of wound product is suitable for Wound management by secondary intention on acute, chronic, full thickness or partial thickness or shallow granulating wounds including pressure ulcers, leg ulcers, diabetic foot ulcers, malignant wounds, surgical wounds, donor sites and fungating ulcers Can be used as a primary or secondary dressing Film border increases adherence Duration dressing remains on wound before changing Can stay in place up to 3-7 days Frequency of dressing change Dependent on exudate levels Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) Care with fragile skin Rationale for inclusion in formulary Can be used for low to moderate exudate levels Different sizes and shapes available Conformability around difficult areas such as heels and elbows Can be used on sacral and buttock wounds where incontinence is an issue due to film backing and border. |
| 05.01.07 | Teicoplanin injection | |
| 05.03.03 | Telaprevir Incivo® | |
| 05.03.03.01 | Telbivudine Sebivo® | |
| A5.01.02 | Telfa | Thin absorbent cotton pad with non adherent film Type of wound product is suitable for Dry or lightly exuding wounds Duration dressing remains on wound before changing 1-7 days Frequency of dressing change As exudate levels determines Caution/contraindications (when not to use the dressing, patient groups to avoid etc.) None Rationale for inclusion in formulary Cost effective. Non adherent dressing for dry or lightly exuding wounds |
| 04.01.01 | Temazepam | From Monday 1 June 2015 prescriptions for temazepam will be required to meet full prescription requirements for Schedule 3 controlled drugs (CDs). |
| 04.01.01 | Temazepam | From Monday 1 June 2015 prescriptions for temazepam will be required to meet full prescription requirements for Schedule 3 controlled drugs (CDs). |
| 05.01.01.02 | Temocillin Negaban® | |
| 08.01.05 | Temozolomide Temodal® | |
| 08.01.05 | Temsirolimus Torisel® | |
| 02.10.02 | Tenecteplase | |
| 05.03.01 | Tenofovir 245mg, Efavirenz 600mg and Emtricitabine 200mg Atripla® | |
| 05.03.01 | Tenofovir and Emtricitabine Truvada® | |
| 05.03.01 | Tenofovir Disproxil Viread® | |
| 09.04 | Tentrini® |
|
| 09.04 | Tentrini® |
|
| 09.04 | Tentrini® |
|
| 09.04 | Tentrini® Energy |
|
| 09.04 | Tentrini® Energy Multi Fibre |
|
| 09.04 | Tentrini® Multi Fibre |
|
| 05.02 | Terbinafine tablets | |
| 13.10.02 | Terbinafine 1% cream | |
| 07.01.03 | Terbutaline | |
| 03.01.01.01 | Terbutaline Inhaler | |
| 03.01.01.01 | Terbutaline Nebulised | |
| 08.02.04 | Teriflunomide Aubagio® | |
| 06.06.01 | Teriparatide Forsteo® | |
| 06.04.02 | Testosterone gel |
|
| 06.04.02 | Testosterone implants | |
| 06.04.02 | Testosterone injection Sustanon 250® | |
| 06.04.02 | Testosterone undecanoate injection | |
| 06.04.02 | Testosterone undecanoate oral Restandol Testocaps® | |
| 14.05.02 | Tetanus immunoglobulin | |
| 04.09.03 | Tetrabenazine | |
| 15.02 | Tetracaine (Amethocaine) Ametop® | |
| 06.05.01 | Tetracosactide Synacthen®, Synacthen Depot® | |
| 05.01.03 | Tetracycline | |
| 13.05.03 | Thalidomide | |
| 08.02.04 | Thalidomide capsules | |
| 03.01.03 | Theophylline Uniphyllin® Continus | |
| 09.06.02 | Thiamine | |
| 09.09 | Thixo-D® |
|
| 06.04.01.01 | Tibolone Livial® | Second line |
| 02.09 | Ticagrelor Brilique® | Use in ACS, The need for a RICaD has been removed (February 2018) following discussion at the APC. Rationale: clinicians are familiar with this drug for this indication. |
| 02.09 | Ticagrelor Brilique® | In line with NICE |
| 05.01.01.04 | Ticarcillin with clavulanic acid Timentin® | |
| 05.01.03 | Tigecycline | |
| 13.05.03 | Tildrakizumab |
|
| 13.04 | Timodine® | Potency: mild |
| 11.06 | Timolol 0.1% unit dose eye gel Tiopex ® | |
| 11.06 | Timolol 0.25% eye drops | |
| 11.06 | Timolol LA 0.25% Eye Drops | |
| 05.01.11 | Tinidazole | |
| 02.08.01 | Tinzaparin | For single dose in suspected DVT. For all other indications. The APC's view is that on clinical grounds, the status for certain indications approved by APC should be amber, supported by an ESCA. HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED.(ESCAs to be developed). |
| 08.01.03 | Tioguanine Tablets | |
| 03.01.02 | Tiotropium Spiriva Respimat® |
|
| 03.01.04 | Tiotropium olodaterol Spiolto®Respimat® | |
| 02.09 | Tirofiban Aggrastat® | |
| 08.01.05 | Tisagenlecleucel Kymriah® | In line with NICE |
| 02.11 | Tisseel | |
| 08.01.05 | Tivozanib Fotivda® | In line with NICE |
| 10.02.02 | Tizanidine tablets | |
| 03.13 | Tobramycin | Commissioned by NHS England for Cystic Fibrosis only. New patients Existing patients (initiated prior to April 2013) |
| 05.01.04 | Tobramycin | |
| 05.01.04 | Tobramycin inhaler TOBI Podhaler® | |
| 10.01.03 | Tocilizumab RoActemra® | Hospital only |
Modified release tablets are non formulary.
2 mcg- unlicensed special
Specialist recommendation - 10 mcg ££
Not NHS
Birmingham CrossCity CCG, Birmingham South Central CCG, Sandwell & West Birmingham CCG
Supported with an ESCA- Solihull CCG (to be developed)
Generic tablets 
